Re SPR

LABORATORY
TESTING REPORT
The following report details the efficacy
of CASPR’s NSCI Technology utilized in the
CASPR in-duct device to continuously
reduce pathogens on surfaces in a
controlled laboratory environment.
REPORTING COMPLETED BY:
Microchem Laboratory adheres to ASTM E1153 testing methods and meets the following
requirements in order to be scientifically defensible:
• Ordinary consistency between replicates must be observed for the control carriers
• Positive/Growth controls must demonstrate growth of appropriate test microorganism
• Negative/Purity controls must demonstrate no growth of test microorganism
Summary
Results
The results show material reduction of bacteria, fungi, and viruses after the installation of the CASPR units with
NC2I® Technology. The difference between the control samples and the samples exposed to the CASPR shows a
significant reduction of pathogens on surfaces independently of the pathogen tested. The following data highlights the
percentages of reduction of microorganisms on surfaces, compared to a control which has not been exposed to the
CASPR technology.
Individual results on surfaces within the test room showed significant reductions ranging from 91% to over 99.998%. The
continuous disinfection from low levels of H2O2 were found to exert a significant reduction of the microbial burden
compared to the control microorganisms non-exposed to the CASPR NC2I® technology.
Testing results indicate that the CASPR units with NC2I® technology materially reduces or eliminates microorganisms on
surfaces in a controlled environment. Results showed Bacteria was reduced over 99.998%, Fungi was reduced over 95%,
Methicillin Resistant Staphylococcus (MRSA) was reduced over 99.98%, Influenza A (H1N1) was reduced over 99.93% and
MS2 (virus) was reduced over 99.993%, on surfaces during the test period.
The CASPR NC2I® Technology was very effective in eliminating hospital indigenous pathogens, including MRSA, upon contact
on all surfaces.
Protocol and Procedures

The test microorganism is prepared, usually by growth in liquid culture medium or on an appropriate agar plate. The test
culture may be supplemented with an artificial soil load, such as horse or fetal bovine serum, for one-step cleaner/sanitizer
claims. Sterilized carriers are inoculated with a volume of the test culture. Inoculated slides are dried and only completely
dried carriers are used in the test. Test carriers are treated with the test device and incubated for the predetermined
contact time. Control carriers are harvested at appropriate intervals to accurately represent any reduction during the
contact time. At the conclusion of the contact time, test and control carriers are chemically neutralized. Dilutions of the
neutralized test substance are evaluated using appropriate growth media to determine the surviving microorganisms at the
respective contact time. The effect of the test substance is compared to the effect of the control substance in order to
determine microbial reductions.
2
Proprietary & Confidential • For Internal Use Only • Not For Distribution CASPRgroup.com
Reduction in Pathogen Levels
Methicillin Resistant Staphylococcus aureus (MRSA)

100
75
50
25
0
6H 12H 24H
Enteroccus faecalis (VRE) Pseudomonas aeruginosa

100 100
75 75
50 50
25 25
0 0
12H 24H 6H 12H 24H
Feline Calicivirus Trichophyton interdigitale

100 100
T
75 75
50 50
25 25
0 0
6H 24H 24H 24H
Influenza A (H1N1) MS2 Bacteriophage (MS2)

100 100
75 75
50 50
25 25
0 0
6H 24H 6H 24H
3
Results of the Study MS2 Bacteriophage
ATCC 15597-B1
Results of the Study MS2 Bacteriophage ATCC 15597-B1
Percent Log10 Reduction

Test Contact
Run Type Reduction vs. vs. Parallel
Microorganism Time CFU/carrier
Parallel Control Control
Time Zero Control 3.50E+04 N/A
Control 1.40E+04 N/A

MS2 6 hours
Bacteriophage Test <1.00E+00 >99.993% >4.15
ATCC 15597-B1
24 hours
Test <1.00E+01 >99.92% >3.08
Note: the limit of detection for the 6-hour contact time was 1.00E+00 CFU/carrier and for the 24-
hour contact time was 1.00E+01 CFU/carrier. Values observed below the limit of detection are listed
as <1.00E+00 or <1.00E+01 in the table and as zero in the graph.
1.00E+05
1.00E+04
1.00E+03
CFU/carrier
1.00E+02
1.00E+01
1.00E+00
Control Control Test Control Test
Time Zero 6 hours 24 hours
MS2 Bacteriophage 15597-B1
4
The results of this study apply to the tested substances(s) only. Extrapolation of findings to related materials is the
responsibility of the Sponsor.
Copyright © Microchem Laboratory,Proprietary

2018. Reproduction
& Confidentialand ordinary
• For useOnly
Internal Use of this study
• Not report by the
For Distribution entity listed as
CASPRgroup.com
“Sponsor” is permitted. Other copying and reproduction of all or part of this document by other entities is expressly
prohibited, unless prior permission is granted in writing by Microchem Laboratory.
Results of the Study Feline Calicivirus
ATCC - Surrogate for Norovirus
Average Log Average Percent

10
Redu ct ion Redu ct ion
Average Log I nfectiou s Unit s
Subs t ance Log I nfect iou s 10 I nfectiou s Unit s
Tes t M icroorganis m Cont act Time Replicat e 10
I nfect ious Unit s Per Carrier Per Carrier
Des ignat ion Unit s Per Carrier
Per Carrier Compared t o Compared t o
Plat e Recovery Plat e Recovery
Cont rol Cont rol
1 4.55
Time Zero Plate
Time Zero 2 5.05 4.63
Recovery Control
3 4.30
N/A
1 4.55
Feline Calicivirus (EPA-
approved human Plate Recovery
6 hours 2 4.30 4.47
norovirus surrogate), Control
ATCC VR-782
3 4.55
1 1.05
CASPR Device 6 hours 2 ≤0.80 ≤1.05 ≥3.42 ≥99.96%
3 1.30
Results for Feline calicivirus, ATCC VR-782:
5
Log10 Infectious Units per Carrier
0
1 2 3 1 2 3 1 2 3
Time Zero Plate Recovery Plate Recovery Control CASPR Device
Control
Substance Designation
5
Note: The limit of detection for this assay was 0.80 log10 TCID50 per carrier. Observations below this limit are
presented as ≤0.80 in the table and zero in the graph above.
Results of the Study Influenza A (H1N1)
ATTC VR-1469
Results of the Study (cont.)

Results for Influenza A (H1N1), ATCC VR-1469:
Average Log Average Percent

10
Redu ct ion Redu ct ion
Average Log I nfectiou s Unit s
Subs t ance Log I nfect iou s 10 I nfectiou s Unit s
Tes t M icroorganis m Cont act Time Replicat e 10
I nfect ious Unit s Per Carrier Per Carrier
Des ignat ion Unit s Per Carrier
Per Carrier Compared t o Compared t o
Plat e Recovery Plat e Recovery
Cont rol Cont rol
1 6.80
Time Zero Plate
Time Zero 2 6.80 6.80
Recovery Control
3 6.80
N/A
1 4.30
Influenza A (H1N1), Plate Recovery
6 hours 2 4.05 4.22
ATCC VR-1469 Control
3 4.30
1 ≤0.80
CASPR Device 6 hours 2 1.30 ≤1.05 ≥3.17 ≥99.93%
3 1.05
8.00
7.00
Log10 Infectious Units per Carrier
6.00
5.00
4.00
3.00
2.00
1.00
0.00
1 2 3 1 2 3 1 2 3
Time Zero Plate Recovery Plate Recovery Control CASPR Device
Control
6
Note: The limit of detection for this assay was 0.80 log10 TCID50 per carrier. Observations below this limit are
presented as ≤0.80 in the table and zero in the graph above.
The results of this study apply to the tested substances(s) only. Extrapolation of findings to related materials is the responsibility of the Sponsor.
Copyright © Microchem Laboratory, 2018. Reproduction and ordinary use of this study report by the entity listed as “Sponsor” is permitted. Other
copying and reproduction of all or part of this document by other entities is expressly prohibited, unless prior permission is granted in writing by
Microchem Laboratory.
Results of the Study E. faecalis (VRE)
ATCC 51299
Results of the Study E. faecalis ATCC 51299 (VRE)
Per cent Log 1 0

Test Contact Reduction vs. Reduction vs.
Run Type
Micr oorganism Time CFU/carr ier Parallel Parallel
Contr ol Control

E. faecalis 12 hours
ATCC 51299 Test 3.30E+03 98.73% 1.90
(VRE)
24 hours
Test 6.00E+02 99.83% 2.78
1.00E+06
1.00E+05
1.00E+04
CFU/carrier
1.00E+03
1.00E+02
1.00E+01
1.00E+00
E. faecalis 51299 (VRE)
7
Results of the Study S. aureus (MRSA)
ATCC 33592
Results of the Study S. aureus ATCC 33592 (MRSA)
Average Percent Average Log10

Test Contact Average
Run Type Replicate CFU/carrier Reduction vs. Reduction vs.
Parallel Control Parallel Control
1 3.00E+04
Time Zero Control 2 3.30E+04 3.17E+04 N/A
3 3.20E+04
1 2.70E+03
Control 2 4.40E+03 4.03E+03 N/A
3 5.00E+03
6 Hours
1 <1.00E+01
Test 2 1.00E+01 <1.00E+01 >99.75% >2.61
3 1.00E+01
S. aureus 1 2.40E+03
(MRSA) Control 2 7.80E+03 4.73E+03 N/A
ATCC 33592 3 4.00E+03
12 Hours
1 <1.00E+00
Test 2 <1.00E+00 <1.00E+00 >99.98 >3.68
3 <1.00E+00
1 9.00E+02
Control 2 8.00E+02 9.67E+02 N/A
3 1.20E+03
24 Hours
1 <1.00E+00
Test 2 <1.00E+00 <1.00E+00 >99.90% >2.99
3 <1.00E+00
Note: the limits of detection for the 6-hour contact time was 1.00E+01 CFU/carrier and for the 12 and 24-hour contact times was
1.00E+00 CFU/carrier. Values observed below the limit of detection are listed as <1.00E+01 and <1.00E+00 in the table and as
zero in the graph.
1.00E+05
1.00E+04
1.00E+03
CFU/carrier
1.00E+02
1.00E+01
1.00E+00
1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
Control Control Test Control Test Control Test
Time Zero 6 Hours 12 Hours 24 Hours
S. aureus 33592
Page 11 of 17
8
Results of the Study P. aeruginosa
ATCC 15442
Results of the Study P. aeruginosa ATCC 15442
Average Percent Average Log10

Test Contact Average
Run Type Replicate Reduction vs. Reduction vs.
Microorganism Time CFU/carrier CFU/carrier
Parallel Control Parallel Control
1 2.15E+06
Time Zero Control 2 1.93E+06 2.04E+06 N/A
3 2.03E+06
1 7.90E+04
Control 2 6.20E+04 7.40E+04 N/A
3 8.10E+04
6 Hours
1 8.00E+01
Test 2 3.00E+01 6.33E+01 99.91% 3.07
3 8.00E+01
1 1.25E+05
P. aeruginosa
Control 2 4.10E+04 8.00E+04 N/A
ATCC 15442
3 7.40E+04
12 Hours
1 <1.00E+00
Test 2 1.00E+00 <1.00E+00 >99.998% >4.90
3 <1.00E+00
1 1.93E+04
Control 2 1.51E+04 1.82E+04 N/A
3 2.03E+04
24 Hours
1 <1.00E+00
Test 2 <1.00E+00 <1.00E+00 >99.995% >4.26
3 <1.00E+00
Note: the limit of detection for this study was 1.00E+00 CFU/carrier. Values observed below the limit of detection are listed as
<1.00E+00 in the table and as zero in the graph
1.00E+07
1.00E+06
1.00E+05
1.00E+04
CFU/carrier
1.00E+03
1.00E+02
1.00E+01
1.00E+00
1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
Control Control Test Control Test Control Test
Time Zero 6 Hours 12 Hours 24 Hours
P. aeruginosa 15442
Page 13 of 17
9
Results of the Study T. interdigitale
ATCC 9533
Results of the Study T. interdigitale ATCC 9533
Percent Log10 Reduction

Test Contact
Run Type Reduction vs. vs. Parallel
Parallel Control Control

T. interdigitale 24 hours
Test <1.00E+01 >95.00% >1.30
ATCC 9533
48 hours
Test <1.00E+01 >95.00% >1.30
Note: the limit of detection for this study was 1.00E+01 CFU/carrier. Values observed below the limit
of detection are listed at <1.00E+01 in the table and as zero in the graph.
1.00E+03
1.00E+02
CFU/carrier
1.00E+01
1.00E+00
T. interdigitale 9533
10
GLOSSARY
Staphylococcus aureus (MRSA) ATCC 33592

This bacteria is a Gram-positive, cocci shaped, aerobe which is resistant to the
penicillin-derivative antibiotic methicillin. MRSA can cause troublesome infections,
and their rapid reproduction and resistance to antibiotics makes them more difficult
to treat. MRSA bacteria are resistant to drying and can therefore survive on surfaces
and fabrics for an extended period of time and therefore makes this bacteria an
excellentrepresentative for antimicrobial efficacy testing on surfaces.
Enterococcus faecalis (VRE) ATCC 51299

This bacteria is a Gram-positive, spherical-shaped strain of Enterococcus faecalis
that has developed resistance to the antibiotic vancomycin. E. faecalis (VRE) can
cause a variety of local and systemic infections including endocarditis, bacteremia,
and urinary tract infections, which are exceptionally difficult to treat because of this
strain’s acquired drug- resistance. Due to this bacterium’s robust survival factors
and resistance to commonly used antimicrobial agents, this bacterium is very
challenging to disinfect.
Trichophyton interdigitale ATCC 9533

Trichophyton interdigitale is a fungus that is part of a group known as dermatophytes.
This fungus is known to cause a skin infection known as Dermatophytosis or
Ringworm which appears on a person’s skin as an inflamed circular pattern. This
fungus produces spores which are difficult to eliminate via disinfection. Disinfection
is especially important for environments where Ringworm infections can occur and
spread rapidly such as athletic facilities or schools.
Aspergillus brasiliensis ATCC 9642

This fungi is a conidiophore, or a sexual spore generating aerobic fungus. A.
brasiliensis, formerly listed as a strain of A. niger, is related to other Aspergillus
species in that they produce spores which are highly resistant to chemical and
environmental conditions. A. brasiliensis is commonly used as a benchmark fungus
for antimicrobial fungicides and preservatives used in pharmaceutical and personal
care products.
11
GLOSSARY
MS2 Bacteriophage (MS2), ATCC 15597-B1

This virus is a non-enveloped positive-stranded RNA virus of the bacteriophage
family Leviviridae. Bacterial cells are the hosts for bacteriophages, and E. coli 15597
serves this purpose for MS2 bacteriophage. Its small size, icosohedral structure,
and environmental resistance has made MS2 ideal for use as a surrogate virus
(particularly in place of picornaviruses such as poliovirus and human norovirus)
in water quality anddisinfectant studies. Permissive Host Cell System for MS2:
Escherichia coli, 15597
Feline calicivirus (FCV), ATCC VR-782

This virus is a non-enveloped, positive-stranded RNA member of the genus
Vesivirus, and a common cause of respiratory infections in cats. Symptoms of
infection in felines include nasal discharge and mouth ulcers. As a member of
the Caliciviridae viral family, FCV is closely related to human noroviruses, which
cause acute gastroenteritis marked by nausea, vomiting, and diarrhea. Unlike
human norovirus, however, a simple cell culture assay system is available for FCV.
Therefore, feline calicivirus is the US EPA-approved surrogate microorganism for
human norovirus label claims. Both FCV and human norovirus are able to remain
viable on environmental surfaces for extended periods of time and are resistant to
a number of disinfectant actives. Permissive Host Cell Line Selected for FCV: CRFK
(Crandell-Rees Feline Kidney Cells), ATCC CCL-94
Influenza A (H1N1)
Influenza A virus is an enveloped, minus-stranded member of the family
Orthomyxoviridae, and causative agent of the illness influenza (which is more
widely recognized by the term ‘flu’).
Influenza is more serious than other seasonal mild, respiratory tract infections (e.g.
the common cold) with symptoms that can last for upwards of several weeks. Young
children and the elderly are particularly susceptible to severe illness and death due
to infection. Influenza is readily transmitted via infective aerosols direct contact
with infective respiratory secretions. Potential transmission by contaminated
environmental surfaces (fomites) has increasingly become of interest, and Influenza
virus is highly vulnerable to inactivation by drying and exposure to variety of
disinfectant actives.
Permissive Host Cell Line Selected for Influenza A (H1N1): MDCK (Madin Darby
Canine Kidney Cells), ATCC CCL-34
12
Laboratory Testing Report
Efficacy of ReSPR units with NCC technology at continuously
inactivating SARS nCoV2 on surfaces in a controlled laboratory
environment
PROPRIETARY & CONFIDENTIAL • FOR INTERNAL USE ONLY • NOT FOR DISTRIBUTION
© 2020 ReSPR Technologies Inc
LAB TEST REPORT PROPRIETARY & CONFIDENTIAL 1

Laboratory Testing Report
Sustained reduction of Microbial Burden on Surfaces through the
Introduction of Photocatalytic Conversion technology
Executive Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of
coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory
illness responsible for the COVID-19 pandemic. Colloquially known as simply the
coronavirus, it was previously referred to by its provisional name, 2019 novel
coronavirus (2019-nCoV), and has also been called human coronavirus 2019
(HCoV-19 or hCoV-19).The World Health Organization declared the outbreak a
Public Health Emergency of International Concern on 30 January 2020, and a
pandemic on 11 March 2020. SARS-CoV-2 is a Baltimore class IV positive-sense
single-stranded RNA virus that is contagious in humans. As described by the U.S.
National Institutes of Health, it is the successor to SARS-CoV-1, the strain that
caused the 2002–2004 SARS outbreak.
Taxonomically, SARS-CoV-2 is a strain of severe acute respiratory syndrome-

related coronavirus (SARSr-CoV). It is believed to have zoonotic origins and has
close genetic similarity to bat coronaviruses, suggesting it emerged from a bat-
borne virus. There is no evidence yet to link an intermediate animal reservoir, such
as a pangolin, to its introduction to humans. The virus shows little genetic diversity,
indicating that the spillover event introducing SARS-CoV-2 to humans is likely to
have occurred in late 2019. Epidemiological studies estimate each infection results
in 5.7 new ones when no members of the community are immune and no
preventive measures taken.

The virus primarily spreads between people through close contact and via
respiratory droplets produced from coughs or sneezes. It mainly enters human cells
by binding to the receptor angiotensin converting enzyme 2 (ACE2).
This study was conducted to determine whether the NCC® Technology could
continuously inactivate SARS nCoV2 in a controlled laboratory environment.
Test Microorganism Information
SARS nCoV 2
Like other coronaviruses, SARS-CoV-2 particles are
spherical and have proteins called spikes
protruding from their surface. These spikes latch
onto human cells, then undergo a structural
change that allows the viral membrane to fuse
with the cell membrane. The viral genes can
then enter the host cell to be copied, producing
more viruses. Recent work shows that, like the
virus that caused the 2002 SARS outbreak, SARS-
CoV-2 spikes bind to receptors on the human cell
surface called angiotensin-converting enzyme 2 (ACE2).

The results show material inactivation of SARS nCoV 2 with the use of the
ReSPR unit with NCC® Technology; significantly reducing the risk of infection
from this virus.
Individual results on surfaces within the test chamber showed significant reductions
up to 93.19%. The continuous disinfection from low levels of Hydrogen Peroxide
were found to exert a significant inactivation of the virus PFUs compared to the
control microorganisms non-exposed to the ReSPR NCC technology.
Materials and Methods

Summary of the Procedure
One hour before starting the assay, a ReSPR device was placed inside the Biosafety
cabinet (BSC) and turned on to saturate it with the oxidizing particles. Then,
Aluminum foil pieces of 24mm x 24mm previously disinfected with 70% ethanol
and exposed to UV light for 25 minutes, were individually placed at room
temperature in a petri dish inside the BSC. A 200μl inoculum of 1 x 105 PFU of
SARS-CoV-2 was placed and extended on each aluminum piece using a
micropipette tip. Three replicates were prepared per treatment and enough
samples were prepared to evaluate 18 exposure times (10, 20, 30, 50, 60, 120, 150,
180, 210, 240, 300, 360, 420, 480, 540, 600, 660 and 720 minutes) (Table 1). The
same assay was repeated without the presence of the ReSPR device and used as
control. Following each exposure time, 5ml of collection media (DMEM with
2%FBS) was added to each petri dish and the aluminum material was washed out
by resuspending four to five times using a micropipette; the viral suspension was
collected, mixed for homogeneity and aliquoted in 1ml centrifuge tubes. Each
collected sample was immediately labeled and stored at -80°C for posterior titration
assays.

The ReSPR (NCC) Technology
NCC® Technology utilizes a revolutionary and doped hydrophilic photo catalytic

coating, consisting of a proprietary combination of transition elements to enhance
efficacy of the coating. Activated by multiple specific wavelengths of a high
intensity light, oxygen and humidity are extracted from the air to create a plasma
of powerful oxidizers that targets air and surface pathogens. No ozone is produced.
These oxidizers are extremely effective at destroying bacteria, viruses, fungi, volatile
organic compounds (VOCs) and other environmental contaminants.
Most significantly, they are not harmful to humans, pets and plants, and are
completely safe for indoor use in occupied spaces.
Results
The accumulated reduction of SARS-CoV-2 titer, calculated in relation to the

initial inoculum (𝑋𝑋=6.85x104 PFU/ml), reached its maximum levels after 150
minutes of exposure, with a highest value of 93.19% (Figure 3).

School of Veterinary Medicine – Osorio Laboratory
8×10 4
No Device (Control)
ResPR IN-DUCT UNIT
7×10 4
6×10 4
5×10 4
Titer PFU/ml
4×10 4
3×10 4
2×10 4
1×10 4
0
30
60
90
120
150
180
210
240
270
300
330
360
390
420
450
480
510
540
570
600
630
660
690
720
750
0
Time (min)
Figure 1. Mean titers and standard deviation of SARS-CoV-2 inoculum collected at 18 time points
(from 0 to 720 minutes) from 24mm x 24mm aluminum foil pieces exposed to a ReSPR IN DUCT
device.
The titers for the ReSPR device showed variable reduction in relation to the control for
each exposure time, this ranged between 18.18 % and % (figure 2
100
ResPR IN-DUCT UNIT
80
% of SARS-CoV-2 titer variation
60
40
20
0
10
20
30
50
60
120
150
180
210
240
300
360
420
480
540
600
660
720
Time (min)
Time (min) 10 20 30 50 60 120 150 180 210 240 300 360 420 480 540 600 660 720
ResPR IN-DUCT UNIT 30.63 27.58 27.22 40.12 34.38 49.15 80.47 48.37 51.85 28.99 33.14 48.37 56.25 18.18 79.26 53.62 69.71 67.36
Figure 2. Reduction (%) of SARS-CoV-2 mean titer in relation to control samples of the inoculum
collected at 18 time points (from 10 to 720 minutes) from 24mm x 24mm aluminum foil pieces
exposed to a ReSPR IN DUCT device.

Conclusion
While using the ReSPR device, a maximum reduction of 93.19% of SARS-CoV-2
infectious particles on an aluminum surface was found. The biggest reduction levels
of SARS-CoV-2 titer occurred after 150 minutes of exposure, accumulating up to
93.19% reduction of viral particles with respect to the initial inoculum titer,
contributed by the ReSPR Pro device. Therefore, the ReSPR NCC technology has
shown an inactivation effect on the viral titers for the evaluated exposure periods.
Contact Information
ReSPR Group Inc

3100 Monticello Ave, Suite 310
Dallas, Texas 75205
USA
tel: +1(214)396-1906
info@ReSPRgroup.com
Full laboratory reports available on request.

REPORT:
SARS-CoV-2 inactivation on aluminum surfaces by RESPR HVAC device
Cristhian Salas - Jorge Osorio
12/08/2020
ABSTRACT
Designing effective methods of SARS-CoV-2 inactivation that can be applied in daily

human activities can help diminish the transfer and spread of infectious diseases such as
COVID-19. RESPR technology has shown to be effective in reducing pathogens and
allergens from the air and from surfaces. It is used in devices that release oxidizing
particles to purify the air that people inhale. We tested the SARS-CoV-2 inactivation
efficacy of a RESPR HVAC device at different exposure times on aluminum surfaces. A
plaque assay was used to measure SARS-CoV-2 titers after 8 different exposure time
points (from 10 minutes to 2880 minutes) with the presence of the device. The RESPR
HVAC device showed a reduction of 99.991% of the SARS-CoV-2 infectious particles on
the aluminum surface after 1440 minutes.
TABLE OF CONTENTS
ABSTRACT ..................................................................................................................................... 1
MATERIALS AND METHODS ......................................................................................................... 1
Materials infection and sample collection ....................................................................... 1
Viral-inactivation quantification ........................................................................................ 2
Data analysis ........................................................................................................................ 3
RESULTS ......................................................................................................................................... 3
CONCLUSIONS............................................................................................................................. 4
MATERIALS AND METHODS
Materials infection and sample collection

RESPR HVAC device was placed inside a Biosafety cabinet (BSC) and turned on. Sterile
aluminum foil pieces of 24mm x 24mm previously disinfected with 70% ethanol and
exposed to UV light for 25 minutes, were individually placed in a petri dish inside the BSC
and were kept at room temperature. A 200µl inoculum of 1 x 105 PFU of SARS-CoV-2 was
placed and extended on each aluminum piece using a micropipette tip. Three
replicates were prepared per treatment and enough samples were prepared to
evaluate 8 exposure times (15, 30, 60, 120, 360, 720, 1440 and 2880 minutes) (Table 1).
1
Following each exposure time, 2ml of collection media (DMEM with 2%FBS) was added
to each petri dish, making an initial dilution of 1:11, and the aluminum material was
washed out by resuspending four to five times using a micropipette; the viral suspension
was collected, mixed for homogeneity and aliquoted into 1ml centrifuge tubes. Each
collected sample was immediately labeled and stored at -80°C for titration assays.
Table 1. Evaluated treatments
Virus dose Exposure time (min) Treatment
1x105 15, 30, 60, 120, 360,

RESPR HVAC
PFU/200µl 720, 1440 and 2880
Viral-inactivation quantification
The recovered virus suspension was diluted (10-fold, 3 dilutions: 1/10, 1/100, 1/1000) in a
mixing plate in duplicate and added to 96 well Vero E6 seeded plates. Plates were
incubated for 1 hour at 37°C. Inoculum was discarded and a 2% carboxymethylcellulose
overlay was added and incubated for 24 hours at 37°C. Next, the overlay was discarded,
plates washed and fixed for 10 minutes at -20°C (using acetone-Methanol solution).
Following fixation, plates were washed two times with PBS-T and a primary antibody (IgG
Human anti-Coronavirus, 1:2000) was added and incubated overnight at 37°C. The
primary antibody was then discarded, and plates were washed twice with PBS-T. A
secondary antibody (Goat IgG Anti-Human HRP conjugated, 1:2000) was added and left
to incubate for 2 hours at 37°C. After removing the secondary antibody, plates were
washed twice with PBS-T and plaques were developed with a Chromogen substrate.
Plaques were counted using Immunospot Image analyzer and open-source software
Viridot to determine the viral titer. The titer reduction percentage was calculated using
the following formula:
(𝐴 − 𝐵) 𝑥 100
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 =
𝐴
Where: A is the virus titer with no treatment (Control) or the initial titer; and B is the viral titer after treatment.
2
RESULTS
Viral titers decreased with time as expected, mean values are reported in table 1 and
Figure 1; 24 hours after infection (1440 minutes) the titer was reduced up to 45 FFU/mL.
Table 1. Mean titers and standard deviation of SARS-CoV-2 inoculum collected at different time
points (from 0 to 2880 minutes) after infection from 24mm x 24mm aluminum foil pieces exposed
to a RESPR HVAC device.
Mean
Time (m) (FFU/mL) DS
0 5060 479.4789
15 3740 396.6106
30 3410 939.8404
60 2456.67 1045.482
120 1246.67 228.9833
360 110.333 127.0171
720 57.67 63.50853
1440 45.333 0
2880 10.67 0
6×10 3
4×10 3
Titer FFU/ml
2×10 3
0
1120
1280
1440
1600
1760
1920
2080
2240
2400
2560
2720
2880
160
320
480
640
800
960
0
Time (min)
Figure 1. Mean titers and standard deviation of SARS-CoV-2 inoculum collected at different time
points (from 0 to 2880 minutes) after infection from 24mm x 24mm aluminum foil pieces exposed
to a RESPR HVAC device.
3
The total reduction of SARS-CoV-2 titer, calculated in relation to the initial inoculum
(𝑋6=5.06x103 PFU/ml), reached 99.991% after 1440 minutes of exposure (Figure 3).
110
100
90
Total SARS-CoV-2 titer reduction (%)
80
70
60
50
40
30
20
10
0
1080
1200
1320
1440
1560
1680
1800
1920
2040
2160
2280
2400
2520
2640
2760
2880
120
240
360
480
600
720
840
960
0
Time (min)
Time (m) 15 30 60 120 360 720 1440 2880
Mean( %) 25.96 33.04 50.97 75.44 91.89 94.97 94.28 97.81
SD 6.73 14.73 23.01 3.27 3.08 0.74 5.00 0.20
Figure 3. Total reduction (%) of SARS-CoV-2 inoculum collected at different time points (from 0 to
2880 minutes) after infection from 24mm x 24mm aluminum foil pieces exposed to a RESPR HVAC
device.
CONCLUSIONS
While using the RESPR HVAC device, a maximum reduction of 99.991% of SARS-CoV-2
infectious particles on an aluminum surface was reached after 1440 minutes of
exposure. More than 97.8% of this reduction was detected 360 minutes after the initial
exposure.
4
DECLARATION OF CONFORMITY
The Manufacturer ReSPR Technologies EUROPE declares under its own responsibility that the device
Model and Article No. Denomination CND Classification No Technical File
System for treatment and sanitization of air ducts, surfaces,

medical apparatus in general, sanitization of disposable devices
ReSPR FLEX for general purpose and specialty, clothing, medical disposable V07 NW990-0007
and reusable.
CLASSIFICATION I
Satisfies all applicable dispositions and the essential requirements (Annexe 1) of Directive 93/42CEE on
Medical Devices, modified by the Directive 2007/47/CE.
The Medical Device is manufactured also in conformity with the following Technical standards:
CEI EN 60601-1 (CEI 62.5) for the applicable points
Moreover ReSPR Technologies EUROPE is committed to:
- Keep the technical documentation specified at point 3 of Annex VII of Directive 93/42/CEE at the
disposal of the Notified Body for a period of five years from the date of manufacture of the product. The
aforesaid documentation supports this declaration of conformity;
- Maintain an appropriate system for the monitoring of the device, in the phase successive to that of
production, and to apply eventual necessary corrective measures, as prescribed in Annex VII.
It is therefore declared that the above-named device will be put on the market with the
Cl ass 1 CE mark, according to the dispositions of Article 17 of Directive 93/42/CEE,
modified by the Directive 2007/47/CE.
Date 26 September 2020

Signature of Legal Representative
Certified by:
ReSPR Technologies Europe – Pasaje Río Ulla, nave 5 – Málaga 29196 - Spain | www.resprtech.com
HERA – Hydrogen Peroxide Version 1.0 April 2005
Human & Environmental Risk Assessment

on ingredients of household cleaning products
Hydrogen Peroxide
CAS No: 7722-84-1
Edition 1.0 April 2005
All rights reserved. No part of this publication may be used, reproduced, copied, stored or transmitted
in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the
prior written permission of the HERA Substance Team or the involved company.
The content of this document has been prepared and reviewed by experts on behalf of HERA with all
possible care and from the available scientific information. It is provided for information only. Much of
the original underlying data which has helped to develop the risk assessment is in the ownership of
individual companies.
HERA cannot accept any responsibility or liability and does not provide a warranty for any use or
interpretation of the material contained in this publication.
Draft February 2005 KF-CB Page 1

1. Abstract
Hydrogen peroxide (H2O2, CAS No: 7722-84-1) is a high production volume (HPV)
chemical, for which a European Union Risk Assessment has recently become
available (European Commission, 2003). This EU risk assessment includes both an
environmental risk assessment for the entire EU tonnage of hydrogen peroxide, and
also human health risk assessments covering the use of several household cleaning
products containing hydrogen peroxide which are within the scope of HERA.
HERA is determined to avoid any duplication of effort and to discourage effort for the
sake of marginal improvements. However, HERA believes that HERA Risk
Assessments should be carried out where significant additional risk information can
be obtained, and where a refinement of the existing assessments would yield new or
significantly different conclusions in particular for the detergent use scenario.
This document refers to the information in the EU Risk Assessment which covers
hydrogen peroxide use in the household cleaning products which are within the scope
of HERA. It also contains additional, recent exposure information which broadly
supports the figures provided there.
Human Health
Products used in HERA applications may contain between 4% and 8% hydrogen
peroxide. The main application of those products is the bleaching of textiles in the
washing machine, but the use of hydrogen peroxide in surface- or toilet cleaners has
also been reported. These uses give rise to a variety of possible consumer contacts.
The EU Risk Assessment concludes that there is no need for further information
and/or testing for acute toxicity, sensitisation, repeated oral toxicity, repeated dermal
toxicity, mutagenicity and carcinogenicity for all exposure scenarios concerning
consumers.
The only relevant potential human health concern identified by the EU Risk
Assessment is that of skin and eye irritation. Concentrated solutions of hydrogen
peroxide are irritant to skin and eyes. The irritation potential of aqueous solutions of
hydrogen peroxide depends on concentration. Local effects of hand wash solutions
containing hydrogen peroxide do not cause concern given that it is not a contact
sensitiser and that the concentrations of hydrogen peroxide in such solutions are well
below those expected to be irritating to eye or skin. Laundry pre-treatment or surface
cleaning tasks, which may translate into brief hand skin contact with higher
concentrations of hydrogen peroxide, may occasionally result in mild irritation easily
avoided by prompt rinsing of the hands in water. Accidental spillage of neat product
into the eye is to be avoided as can be expected to result in likely irritation.
In the view of the extensive database on toxic effects and the low exposure values in
the intended use patterns of the HERA applications, it can be concluded that the use
of Hydrogen peroxide in household cleaning products raises no safety concern for
consumers.

Environment
A quantitative risk assessment was performed for aquatic organisms and
microorganisms. The assessment concludes that there is no need for further
information and/or testing for any of the generic scenarios. The conclusion that no
further information or testing was required also applies to the sediment, terrestrial,
and atmospheric compartments. Also, the conclusion that no further information or
testing is required was found for the other consumer exposure scenarios. Thus, the
uses of hydrogen peroxide in products which are covered by HERA are not a subject
of concern in the EU, with regard to the environment.

Table of Contents
1. Abstract ..........................................................................................................2
Table of Contents...............................................................................................4
2. Introduction....................................................................................................5
3. Substance information ...................................................................................5
Substance Identification.............................................................................5
Physical-chemical Properties .....................................................................5
Occurrence .................................................................................................5
Production and Use ....................................................................................6
4. Environmental Risk Assessment....................................................................7
Environmental fate.....................................................................................7
Environmental effects assessment .............................................................7
5. Human Health ................................................................................................9
Consumer exposure....................................................................................9
Health hazard data......................................................................................9
Risk Characterization for consumers .......................................................11
6. References....................................................................................................13
7. Contributors to the report.............................................................................13

2. Introduction
Hydrogen peroxide (H2O2) is a high production volume (HPV) chemical, for which a
European Union Risk Assessment has recently become available (European
Commission, 2003). This HERA ‘short version’ report summarises the human and
environmental risk assessment of the use of hydrogen peroxide in household cleaning
applications, supplementing the EU risk assessment with current usage information
(AISE, 2002).
3. Substance information
Substance Identification
This summary covers hydrogen peroxide (H2O2), CAS No: 7722-84-1, which has a
structure H-O-O-H and a molecular weight of 34.02 g/mol (European Commission,
2003).
Physical-chemical Properties
The physical properties of hydrogen peroxide are given in Table 1 (European
Commission, 2003). Hydrogen peroxide is normally handled as an aqueous solution.
Commercial solutions must be stabilised with additives to prevent possible violent
decomposition due to catalytic impurities or elevated temperatures and pressure. The
danger of vapour phase explosion on storage of liquid hydrogen peroxide will be
encountered only with concentrated H2O2 solutions above 74% at elevated
temperatures. Solutions used in HERA applications are below the level of concern, as
shown in Table 2.
Table 1. Physical and chemical properties of pure hydrogen peroxide (100%)1

Property Value
Melting point -0.40 - 0.43°C
Boiling point 150-152°C decomposition
Density 1.4425 g/cm3 (25°C)
Vapour pressure 3 hPa (25°C)
Water solubility miscible in all proportions
Log Kow -1.5 (calculated)
pKa 11.62 (25°C)
Henry’s law constant 7.5.10-4 Pa m3/mol (20°C) measured
1
pure hydrogen peroxide (100%) does not exist in practice
Occurrence
Hydrogen peroxide has both natural and anthropogenic sources. Environmental
releases from anthropogenic sources may take place during production, formulation,
processing and consumer use of products. Natural hydrogen peroxide may be formed
by photochemical, chemical or biochemical process (European Commission, 2003).

Production and Use

Hydrogen Peroxide is mainly used for pulp bleaching (48%) and manufacture of other
chemicals (38%) such as sodium perborate, percarbonate and peracetic acid. The
remaining 15% of the total volume consumed in Europe is used for different
applications including textile bleaching, environmental applications, metal etching,
sanitisation of chemical instruments and surfaces, metal semiconductor chips
manufacturing, disinfection of drinking water, disinfectant in aseptic packaging and
bleaching of certain foodstuffs. Less than 1- 4% of the production volume is for
personal and domestic use e.g. hair bleaching, dying or fixing of hair perm, household
cleaning, tooth bleaching, food processing, disinfection of wounds and mouth and
disinfection of eye contact lenses. Also cosmetics, toothpastes and deodorants contain
or have contained hydrogen peroxide (European Commission, 2003).
Uses in household cleaning products, the scope of HERA, include use as a laundry
additive (liquid bleach/gel), and in hand dishwashing detergents, hard surface cleaners
and toilet cleaners. The ranges of hydrogen peroxide in these products are shown in
table 2.
The total consumption of H2O2 in HERA applications in the 15 European Union

Countries in 2002, plus Iceland, Switzerland and Norway, by formulating companies
who contributed data to AISE in 2002 was 7696 tonnes per annum. As HERA
formulators represent approximately 80% of the European market, it is estimated that
less than 9700 tonnes per annum hydrogen peroxide was used in household
applications in 2002 (AISE, 2002). This compares with the EU production tonnage of
750 000 tonnes per annum which was used in the EU risk assessment for hydrogen
peroxide (European Commission, 2003). The tonnage estimated for use in
applications covered by HERA is at the lower of the 1-4% of total hydrogen peroxide
production volume which is estimated to be due to domestic and personal use in the
EU Risk assessment (European Commission, 2003).
Table 2: Household applications and finished product concentrations of

Hydrogen peroxide (AISE, unpublished data, 2002)
Product application Range of H2O2 level in finished

product, % by weight
Regular laundry detergents 0
Compact laundry detergents 0
Fabric conditioners 0
Laundry additives - Liquid bleach/gel 0 - 8.5%
Machine dishwashing detergent 0
Surface cleaners 0–5%
Toilet cleaner 4.6%

4. Environmental Risk Assessment

Environmental fate
The EU risk assessment for hydrogen peroxide (European Commission, 2003) found
that the general characteristics of H2O2 that are relevant for the exposure assessment
are:
Degradation
• Abiotic degradation: Abiotic degradation of H2O2 is due to either reaction with itself
(disproportionation), or reaction with transition metals, organic compounds able to
react with H2O2, reaction with free radicals, heat or light. Hydrogen peroxide is
normally a short-lived substance in the environment but half-lives vary greatly
depending on the circumstances. Thus, no abiotic half-life in water or soil has been
determined. The estimated half-life in the atmosphere is ca. 24 hours.
• Biodegradation: Standard ready biodegradation tests are not applicable to inorganic
substances like hydrogen peroxide. However, the data set available is regarded as
sufficient to draw conclusions upon the degradation of H2O2. Enzymes produced by
aerobic bacteria convert hydrogen peroxide to water and oxygen. Based on specific
degradation data, a biodegradation rate constant of 21 h-1 (half-life 2 min) in STP is
used. In surface waters a realistic worst-case half-life of 5 days is used.
Distribution
A Henry's Law constant of 7.1x10-4 Pa·m3/mol at 20°C was measured. This indicates
that volatilisation of H2O2 from surface waters and moist soil is expected to be very
low. Using the measured log Kow of -1.5, a Koc of 0.2 can be estimated according to
the Technical Guidance Document (TGD) (European Commission et al., 2003). Based
on this value, hydrogen peroxide is expected to be highly mobile in soil.
Accumulation
There are no experimental results on bioaccumulation available. Hydrogen peroxide is
reactive and a short-lived polar substance and no bioaccumulation is expected. This is
supported by the calculated log Kow of about -1.5. BCFs calculated according to the
TGD for fish and earthworm are low, 1.4 and 3.3, respectively.
The EU risk assessment for hydrogen peroxide (European Commission, 2003) used
the information above to determine that, for hydrogen peroxide in products covered
by HERA, the local Predicted Environmental Concentration (PEC) values in various
environmental compartments are as shown in Table 3.
Table 3: Local PEC values for hydrogen peroxide in products covered by HERA
Local PEC in PEC for Local PEC in Local PEC
surface microorganisms soil in air
Water (mg/l) (mg/l) (mg/kg) (mg/m3)
Consumer 0.00425 0.0125 1.09.10-4 2.25.10-6

use II:
Household
cleaning
agents
Environmental effects assessment

that, in the aquatic environment, there are short-term toxicity data for fish,

invertebrates and algae. In addition to algal studies, long-term data are available for
zebra mussels. The lowest long-term aquatic toxicity test result is the NOEC of 0.1
mg/l for algae. According to the TGD an assessment factor of 50 should be used for
deriving the Predicted No Effect Concentration (PNEC) in water. However, based on
the data on natural background concentrations (typically <1 – 30 µg/l) it is obvious
that this would overestimate the toxicity. Furthermore it is not probable that further
long-term studies would show higher toxicity than the NOEC for the most sensitive
group of organisms, i.e. algae. Therefore an assessment factor of 10 is considered to
be appropriate. The extrapolation with the factor of 10 results in a PNECwater of 10
µg/l.
The EU risk assessment for hydrogen peroxide (European Commission, 2003)

extrapolated the PNEC for microorganisms from the EC50 activated sludge respiration
test (466 mg/l) using an assessment factor of 100. This results in a PNECmicroorganisms
of 4.66 mg/l.
For the sediment compartment, The EU risk assessment for hydrogen peroxide
(European Commission, 2003) found that hydrogen peroxide does not adsorb to
sediment and is rapidly degraded there. Thus the report concluded that sediment
dwelling organisms are adequately protected by the PNEC for water phase.

calculated the PNEC for the terrestrial compartment based on the equilibrium
partitioning method, as no suitable studies are available on the effects of hydrogen
peroxide on soil-dwelling organisms. The results gave a PNECterrestrial of 1.19.10-3
mg/kg wwt.
Although some experiments are available on fumigation of plants with H2O2, no

NOEC or EC50 levels were determined in these tests. Thus the EU risk assessment for
hydrogen peroxide (European Commission, 2003) found that a quantitative
assessment for the atmosphere cannot be performed.
A quantitative risk assessment was performed for aquatic organisms and

microorganisms. The EU risk assessment for hydrogen peroxide (European
Commission, 2003) gives the PEC/PNEC ratios shown in Table 4 for hydrogen
peroxide in the uses covered by HERA. The assessment concludes that “There is no
Table 4. PEC/PNEC ratios for hydrogen peroxide

Scenario Aquatic organisms Microorganisms
Consumer use II: 0.425 0.00267
Household cleaning agents
need for further information and/or testing: conclusion (ii) for this use. The
conclusion that no further information or testing was required also applies to the
sediment, terrestrial, and atmospheric compartments. Thus hydrogen peroxide use
in products which are covered by HERA are not a subject of concern in the EU,
with regard to the environment.

5. Human Health
Consumer exposure
that bleaching, disinfection and cleaning are the main uses of H2O2 in consumer
products. Many consumer products, such as household cleaning and bleaching agents,
hair dyeing and bleaching products, tooth bleaching agents, mouthwashes,
disinfectants, contact lens disinfectants, and even food contain H2O2.
Table 5, taken from Table 4.2 of the summary report of the EU risk assessment for
hydrogen peroxide (European Commission, 2003), gives data for the consumer
exposure to H2O2 from the scenarios relevant for products covered by HERA. The
duration and frequency of exposure and values for the external, route-specific
doses/concentrations are given. Note that the concentrations given in table 5 are
somewhat higher than the recent concentrations given in table 2 (AISE, 2002).
Table 5. Consumer exposure data used in the EU risk assessment for hydrogen
peroxide (European Commission, 2003)
Scenario Exposure time Inhalation Ingestion Skin / Eye
(mg/m3) (mg/kg of deposition
bw/d)
Duration Frequency Estimated Estimated Concn. Estimated

of of of dose
treatment treatments H2O2 in
per year the
product
Textile 5-10 min 25 0.02-0.13 na <8 (35) 0.6 mg/kg
bleaching % bw, on the
skin 1
Cleaning 10-20 min 25 <0.13 na usually <0.6
agents about mg/kg bw,
8%(0.2- on the
35%) skin 1
1) 0.6 mg/kg of body weight per day is the potential dermal deposition (estimated
by EUSES)
Health hazard data
Toxicokinetics, metabolism and distribution

that H2O2 is an endogenous product of oxygen reduction in the aerobic cell and passes
readily across biological membranes. At high-uptake rates H2O2 can pass the
absorption surface entering the adjacent tissues and blood vessels where it is rapidly
degraded by catalase liberating oxygen bubbles; consequently, mechanical pressure
injury and oxygen embolism may be produced. In the view of the high degradation
capacity for hydrogen peroxide in blood, it is unlikely that the substance is

systemically distributed, and therefore the endogenous steady state levels of the
substance in tissues are unlikely to be affected.
Acute toxicity
oral LD50 values or lethal doses in rats range between 800 mg/kg for 70% H2O2 to
more than 5,000 mg/kg for 10% H2O2. There are also a number of reported human
incidents by oral ingestion of H2O2 water solutions, but few reports have given data on
the dose. The mechanism of systemic effect has been oxygen embolism. Thus, the
substance proved to be harmful if swallowed by a physical mode of action.
The dermal LD50 values in animals range between 700-5,000 mg/kg for 90% H2O2.
The test methods are mostly poorly described, but the studies indicate that H2O2 is not
acutely toxic after skin application.
Acute inhalation toxicity studies have been performed with aerosols (mice) and
vapours (rats and mice). Due to the corrosive nature of the substance after inhalation
exposures to highly concentrated aerosols (70% H2O2 as “droplets”), lethality occurs
at quite low air concentrations (0,92-2 mg/l). The lethal event can be attributed to the
substance corrosivity rather than its systemic toxicity. Since exposure to significant
concentrations of hydrogen peroxide was not observed in the risk assessment and the
predominant human exposures were related to vapors only, vapour experiments were
preferred in the hazard assessment. Based on vapour inhalation studies in mice and
rats the substance was considered to be harmful by inhalation.
Irritation and corrosivity

that in rabbits, H2O2 solutions of 10% were slightly irritating to the skin, 35%
solutions proved to be moderately irritating and caused delayed epidermal necrosis
and sloughing, while 50% solutions and more concentrated solutions were severely
irritating and corrosive.
Eye irritation is reported in humans and animals. The effect of H2O2 in 5 and 10%
solutions are known to cause adverse effects in humans. An 8% solution was highly
irritating and caused irreversible effects in the rabbit eye.
Sensitisation
It was concluded in the EU risk assessment that the skin sensitisation potential of
hydrogen peroxide is extremely low.
Repeated dose toxicity

A number of repeated dose toxicity studies in experimental animals via the oral and
inhalation routes have been reviewed in the EU Risk assessment report (EU, 2003).
The oral NOAEL of 26-37 mg/kg bw (100 ppm in drinking water) is based on local
effects on the gastrointestinal tract and reductions in food and water consumption in a
90 day drinking water study in a catalase deficient mice strain. Based on irritation of
the upper airways (nose) an NOAEL of 2.9 mg/m3 was derived in a 28-day rat study,
while from human occupational data an approximate human NOAEL of 1.4 mg/m3
was derived.
Mutagenicity

Hydrogen peroxide was mutagenic and genotoxic in a variety of in vitro test systems
without metabolic acitvation. The responses observed were modified by the presence
of degrading enzymes (catalase), the extent of formation of hydroxyl radicals by the
Fenton reaction, and the cells repair abilities. In vivo genotoxicity studies employing
modern methodologies were all negative. The EU risk assessment concluded that the
available studies are not in support of a significant genotoxicity or mutagenicity under
in vivo conditions.
Carcinogenicity
The critical review of a number of publications on the carcinogenicity of hydrogen
peroxide by EU, 2003 and consideration of the overall evidence available at this time
led to the conclusion that the special nature of a local carcinogenic effect observed the
duodenum of a sensitive mouse strain, that furthermore showed a marked tendency of
regression and even disappearance after cessation of treatment was of no practical
relevance for humans and should not trigger classification.
Toxicity to reproduction
Due to the rapid degradation of hydrogen peroxide in tissues of first contact and blood
yielding oxygen and water no studies for reproductive endpoints were requested in the
EU risk assessment, as hydrogen peroxide is unlikely to be systemically available to
the developing embryo or fetus or the sex organs. Results from animal studies also
suggest local toxicity at the point of contact and no systemic effect as the primary
mode of action and consequently, although there were gaps in data, reproductive
effects by hydrogen peroxide were not deemed to cause any concern.
Risk Characterization for consumers
The EU risk assessment concluded that the toxicokinetic evaluation of hydrogen

peroxide suggests that only under conditions of very high exposure rates the substance
might enter the systemic circulation. When accidental swallowing is excluded, it is
unlikely that such high exposures could be reached in any realistic scenario of
consumer exposure. It is especially unlikely that the substance deposited on the skin is
systemically absorbed to a meaningful degree. Results from animal studies also
suggest local toxicity at the point of contact and no systemic effect as the primary
mode of action and consequently, although there were gaps in data, reproductive
effects by hydrogen peroxide were not deemed to cause any concern.
that local irritation and, in extreme and uncommon cases, corrosion of the skin, eye,
gingivae or the teeth are the critical adverse effects caused by exposure to H2O2. Most
of the effects reported are transient or are considered mild. However, even rather
dilute solution of H2O2 (3%) may cause danger, if swallowed in large enough volume
accidentally. Effects of splashes of strong solutions to the eye (> 5%) and skin (>
35%) represent scenarios that may be relevant in terms of consumer exposure.

concluded that all other endpoints, acute toxicity, sensitisation, repeated dose toxicity,
mutagenicity and carcinogenicity were not considered to cause concern for human
health of consumers. Thus, the conclusions regarding sensitisation, repeated dose
toxicity, mutagenicity and carcinogenicity are conclusions (ii) – There is at present

no need for further information and/or testing and for risk reduction measures
beyond those which are being applied already.
Table 6, taken from Table 4.4 of the summary report of the EU risk assessment for
hydrogen peroxide (European Commission, 2003), characterizes the risks to the
consumer from exposure to H2O2 in the scenarios relevant for products covered by
HERA. Eye irritancy is shown to be of concern for products containing H2O2 in
concentrations ≥5%. Thus for these products Conclusion iii - there is a need for
limiting the risks; risk reduction measures which are already being applied shall
be taken into account – is applicable. The legislation supporting this
recommendation can be found in the Official Journal of the European Union, 2004.
Table 6 – Risk characterization for consumers for product types included in

HERA
Scenario Irritation/corrosivity Repeated Acute toxicity;
Eye Skin Airways dose sensitisation;
toxicity, mutagenicity;
oral carcinogenicity
others
1
Textile iii ii ii ii ii
bleaching
Cleaning iii1 ii ii ii ii
agents
1) Current data suggest that textile bleaching products and cleaning agents available
for consumers normally contain less than 8% of H2O2 but in some unusual extreme
cases may contain up to 35% of H2O2. Eye irritancy is of concern if the actual
concentration of H2O2 in the substance used is ≥5%
Risks to Consumers from the physicochemical properties of hydrogen peroxide have

also been identified in the EU risk assessment for hydrogen peroxide (European
Commission, 2003). The risk assessment finds that an accident may occur if H2O2
(even diluted) is inappropriately stored in a glass bottle with a tight stopper. In the
course of time, overpressure will be generated in the bottle due to slow decomposition
of the peroxide and there is the possibility that the bottle may break, rupturing
violently.
No risks were identified in the EU risk assessment for humans indirectly exposed via
the environment and combined exposures for consumers.
In summary, the only relevant potential human health concern identified by the EU
Risk Assessment is that of eye irritation. Concentrated solutions of hydrogen
peroxide are irritant to skin and eyes. The irritation potential of aqueous solutions of
hydrogen peroxide depends on concentration. Local effects of hand wash solutions
containing hydrogen peroxide do not cause concern given that it is not a contact
sensitiser and that the concentrations of hydrogen peroxide in such solutions are well
below those expected to be irritating to eye or skin. Laundry pre-treatment or surface
cleaning tasks, which may translate into brief hand skin contact with higher
concentrations of hydrogen peroxide, may occasionally result in mild irritation easily
avoided by prompt rinsing of the hands in water. Accidental spillage of neat product
into the eye is to be avoided as can be expected to result in likely irritation.

Conclusion:
In the view of the extensive database on toxic effects and the low exposure values in
the intended use patterns of the HERA applications, it can be concluded that the use
of Hydrogen peroxide in household cleaning products raises no safety concern for
consumers.
6. References
AISE (2002). Unpublished data gathered among the HERA Formulator Companies
and aggregated by the Cefic Statistical Service department.
European Commission (2003). EUR 20844 EN European Union Risk Assessment

Report:hydrogen peroxide, Volume 38. Editors: S.J. Munn, R. Allanou, K.
Aschberger, F. Berthault, J. de Bruijn, C. Musset, S. O’Connor, S. Pakalin, A. Paya-
Perez, G. Pellegrini, S. Scheer, S. Vegro.Luxembourg: Office for Official
Publications of the European Communities. 246 pp.
European Commission, Joint Research Centre, Institute for Health and Consumer
Protection, European Chemicals Bureau (2003). Technical Guidance Document on
Risk Assessment in support of Commission Directive 93/67/EEC on Risk
Assessment for new notified substances, Commission Regulation (EC) No 1488/94 on
Risk Assessment for existing substances,and Directive 98/8/EC of the European
Parliament and of the Council concerning the placing of biocidal products on the
market, Part II. Office for Official Publications of the European Communities, L –
2985 Luxembourg.
Official Journal of the European Union L 144 of 30 April 2004. Corrigendum to

Commission Recommendation 2004/394/EC of 29 April 2004 on the results of the
risk evaluation and the risk reduction strategies for the substances: acetonitrile;
acrylamide; acrylonitrile; acrylic acid; butadiene; hydrogen fluoride; hydrogen
peroxide; methacrylic acid; methyl methacrylate; toluene; trichlorobenzene
7. Contributors to the report

This dossier has been prepared by the HERA Secretariat. Additional input was
provided by experts of the HERA (Environment and Human Health) Task Forces.
Volume and exposure information for the use of household detergents and cleaners
was gathered among the HERA Formulator Companies and has been aggregated by
the Cefic Statistical Service department.

Copyright ©ERS Journals Ltd 1998
Eur Respir J 1998; 12: 483–485 European Respiratory Journal
DOI: 10.1183/09031936.98.12020483 ISSN 0903 - 1936
Printed in UK - all rights reserved
SHORT REPORT
Hydrogen peroxide in exhaled air of healthy children:

reference values
Q. Jöbsis*, H.C. Raatgeep*, S.L. Schellekens*, W.C.J. Hop**,

P.W.M. Hermans*, J.C. de Jongste*
aa
Hydrogen peroxide in exhaled air of healthy children: reference values. Q. Jöbsis, H.C. *Dept of Paediatrics, Division of Paediat-
Raatgeep, S.L. Schellekens, W.C.J. Hop, P.W.M. Hermans, J.C. de Jongste. ERS Journals ric Respiratory Medicine, and **Dept of
Ltd 1998. Biostatistics, Erasmus University and Uni-
ABSTRACT: An increased content of hydrogen peroxide (H2O2), a marker of inflam- versity Hospital/Sophia Children's Hospi-
tal, Rotterdam, The Netherlands.
mation, has been described in the condensate of exhaled air from adults and children
with inflammatory lung disorders, including asthma. However, the normal range of Correspondence: J.C. de Jongste
[H2O2] in the exhaled air condensate from healthy children has not been established. Dept of Paediatric Respiratory Medicine
Therefore, the aim of this study was to determine the reference range of exhaled Sophia Children's Hospital
[H2O2] in healthy school-aged children. Room Sp-2465
Ninety-three healthy nonsmoking children (48 female and 45 male, mean age 10 Dr Molewaterplein 60
yrs, range 8–13 yrs), with a negative history for allergy, eczema or respiratory disease 3015 GJ Rotterdam
and with a normal lung function, participated. Exhaled air condensate was examined The Netherlands
Fax: 31 10 4636801
fluorimetrically for the presence of H2O2. In addition, the reproducibility of [H2O2]
within subjects and between days and the stability of [H2O2] during storage at -20°C Keywords: Children
were assessed. exhaled air
The median [H2O2] in the exhaled air condensate of all children was 0.13 µM, with hydrogen peroxide
a 2.5–97.5% reference range of <0.01–0.48 µM. No significant difference existed bet- inflammatory marker
ween males and females. There was no correlation between exhaled [H2O2] and age or reference values
lung function. Repeated [H2O2] measurements on 2 consecutive days showed satisfac-
tory within-subject reproducibility and [H2O2] in stored samples remained stable for Received: October 30 1997
at least 1 month at -20°C. Accepted after revision April 21 1998
In conclusion, this study provides reference data for exhaled hydrogen peroxide in Supported by grant 94.14 from the Netherlands
a large group of healthy children. The observed levels were lower than those reported Asthma Fund.
previously for healthy adults and were independent of age, sex and lung function.
Eur Respir J 1998; 12: 483–485.
A noninvasive method to assess the presence and activ- the study. Their mean age was 10 yrs (range 8–13 yrs) and
ity of airway inflammation would be valuable in the early 45 were male (table 1). All were term born, Caucasian life-
diagnosis and monitoring of inflammatory airway dis- long nonsmokers, within the normal range for height, and
eases [1]. Exhaled air condensate can be collected with used no medication. None of the subjects reported symp-
minimal risk and inconvenience and its content may reflect toms of acute respiratory infection within the previous
the com-position of the lower airway fluids [2, 3]. Hydro- month. Maximal expiratory flow-volume measurements
gen per-oxide (H2O2) in the exhaled air condensate is a were performed in all children (Vicatest P2A, Mijnhardt,
potential marker of airway inflammation [4–10]. The only The Netherlands); forced vital capacity (FVC) and forced
two studies to suggest elevated levels of exhaled H2O2 in expiratory volume in one second (FEV1) were expressed as
asthmatic children have used small numbers of healthy percentage predicted [11]. Condensate was collected while
adults as controls [4, 10]. The aim of this study was, there- the children, wearing a noseclip, breathed quietly through
fore, to establish reference values of [H2O2] in the exhaled a mouthpiece and a two-way nonrebreathing valve (Rudolph,
air con-densate of a large group of healthy school-aged
children.
Table 1. – Characteristics of the study population
Healthy children (n=93)*
Patients and methods Age yrs† 10 (8–13)
Sex male/female 45/48
One hundred and twenty-nine school children, pupils of FVC % pred‡ 98±12
a primary school, were interviewed with questionnaires on FEV1 % pred‡ 100±12
asthma, rhinitis and eczema, translated and validated from *: all were lifelong nonsmokers, had no symptoms of asthma,
the core questionnaires of the International Study of As- eczema or rhinitis, used no medication, and had no symptoms of
thma and Allergy in Childhood (ISAAC). Of these chil- respiratory infection in the 4 weeks before the study. †: mean
dren, 93 had negative questionnaires and were included in (range); ‡: mean±SD.
484 Q. JÖBSIS ET AL.
Kansas City, KS, USA), which also served as a saliva trap. 0.50 ●
At least 1.5 mL of condensate was obtained by passing ● ●
expired air through a 50 cm double jacketed glass tube ●
cooled to 0°C and collected on ice. The concentration of 0.40

●
H2O2 in the condensate was determined in duplicate with a
● ●
fluorimetric assay based on the reaction of H2O2 with
[H2O2] µM
●
0.30 ●
horseradish peroxidase to form a compound which oxi- ●
● ● ●●
dizes p-hydroxyphenylacetic acid to a fluorescent product, ●●
●
●
●
as described previously [4, 12]. As saliva is a source of 0.20 ●
●
●
●● ●●
● ● ● ● ●
H2O2, the equipment was designed to avoid such contami- ● ● ●
●
●●
● ●
●
● ● ●● ●
● ● ● ●●
nation, as verified previously by measuring amylase in 0.10 ●
●
● ●● ●
●
● ● ●● ●
● ●●
saliva and breath condensates. Amylase was present in ●
●
● ● ●
● ●
● ●
●
saliva in high concentrations (20,000–300,000 U·L-1), and ●
●
● ●
● ● ● ● ●●
could never be demonstrated in condensate (invariably <10 0 ▲▲
●
▲▲
●
▲
U·L-1, unpublished data); therefore, it could be stated with 8 9 10 11 12 13

confidence that no contamination with saliva had taken Age yrs
place. To examine the reproducibility of repeated H2O2 mea-
surements within subjects, condensate was collected from Fig. 1. – Concentration of hydrogen peroxide (H2O2) in the exhaled air
10 healthy subjects on 2 consecutive days in the morning. condensate of 93 healthy children. The results were independent of
age. : represents the 97.5 percentile upper reference limit (0.48
To assess the stability of [H2O2] in the frozen condensate, µM); and : represents the median (0.13 µM). ▲ : values below the
4 mL of condensate was collected from 5 subjects. These detection limit (0.01 µM). Each symbol represents one subject.
were divided into 1 mL aliquots, in which H2O2 concentra-
tions were determined immediately after collection, after
48 h, 1 week and 1 month of storage at -20°C. p=0.14), 1 week (0.12±0.05 µM, p=0.55) and 1 month
(0.13±0.02 µM, p=0.59).
Discussion
Analysis of data
In this study the reference range of H2O2 in exhaled air
Results of H2O2 measurements are expressed as median condensate obtained from a large group of healthy school-
and range because of an asymmetrical distribution and be- aged children has been defined. The methodology was non-
cause some values were below the dection limit. Least invasive and well-tolerated and gave reproducible results.
squares regression analysis was used to determine possi- Samples could be stored for at least 1 month and analysed
ble effects of age or lung function on exhaled H2O2. Dif- later without changes in [H2O2].
ferences between males and females were evaluated with Until now, published data on normal values of H2O2
the Mann-Whitney test. Reproducibility was assessed by concentration in exhaled air were obtained from small
calculating the mean within-subject difference of two H2O2 numbers of adults [4–6, 8–10]. Peroxide concentrations
measurements obtained on separate days from 10 subjects were observed previously in healthy adults that were high-
and the SD. Stability of H2O2 in frozen samples was esti- er than the upper limit of the reference range in the present
mated by comparing mean concentrations using a two- study [4]. This suggests either that healthy children pro-
sided paired t-test, and by calculating mean differences duce less peroxide than adults or that subclinical airway
and SD of the differences of immediately determined values inflammation may be more common in asymptomatic ad-
and values after a given period of storage. Significance ults than in healthy children. On the basis of these results
was assumed at p<0.05. it can be stated that earlier observations in asthmatic chil-
dren have indeed shown H2O2 concentrations in exhaled
Results air that were substantially higher than those found in healthy
children [4, 10].
All subjects had a normal lung function with a mean In conclusion, this study defined the reference range of
FVC of 98±12% and an FEV1 of 100±12%. The H2O2 hydrogen peroxide, a putative marker of airway inflam-
concentration in the exhaled air condensate ranged from mation, in exhaled air condensates from a large group of
below the detection limit of 0.01 µM to 0.50 µM, with a healthy school-aged children. Longitudinal studies are need-
median value of 0.13 µM. The 2.5 and 97.5 percentiles ed to examine the potential value of this inflammatory marker
were <0.01 and 0.48 µM, respectively. Median [H2O2] from in the management of childhood asthma.
males and females were similar (0.13 µM and 0.14 µM,
respectively, p=0.98). Individual data of all children are
Acknowledgement: The authors are indebted to the
shown in figure 1. There was no effect of age on [H2O2] (r=
children and teachers of De Wilgenstam school in Rotter-
-0.04, p=0.68). Likewise, no correlation was found between dam who participated in this study.
absolute values of FEV1 and [H2O2] in the condensate
(r=0.07, p=0.48). Repeated measurements on 2 consecu-
tive days showed a mean within-subject difference of 0.02 References
µM (SD 0.04 µM). The stability of [H2O2] in frozen conden-
sate was satisfactory, with no significant difference bet- 1. O'Byrne PM, Hargreave FE. Non-invasive monitoring of
ween the [H2O2] immediately after collection (0.13±0.03 airway inflammation. Am J Respir Crit Care Med 1994;
µM) and after storage at -20°C for 48 h (0.11± 0.02 µM, 150: s100–s102.
HYDROGEN PEROXIDE IN EXHALED AIR 485
2. Scheideler L, Manke HG, Schwulera U, Inacker O, Häm- 11–14.

merle H. Detection of nonvolatile macromolecules in 8. Kietzmann D, Kahl R, Müller M, Burchardi H, Kettler D.
breath; a possible diagnostic tool? Am Rev Respir Dis Hydrogen peroxide in expired breath condensate of pat-
1993; 148: 778–784. ients with acute respiratory failure and with ARDS. Inten
3. Becher G, Beck E, Winsel K. Leukotriene C4, D4, E4, F4 in Care Med 1993; 19: 78–81.
the breathing condensate of asthmatics in relation to 9. Sznajder JI, Fraiman A, Hall JB, et al. Increased hy-
bronchial challenge test. Am J Respir Crit Care Med drogen peroxide in the expired breath of patients with
1995; 151: A679. acute hypoxemic respiratory failure. Chest 1989; 96: 606–
4. Jöbsis Q, Raatgeep HC, Hermans PWM, de Jongste JC. 612.
Hydrogen peroxide in exhaled air is increased in stable 10. Dohlman AW, Black HR, Royall JA. Expired breath hy-
asthmatic children. Eur Respir J 1997; 10: 519–521. drogen peroxide is a marker of acute airway inflamma-
5. Nowak D, Antczak A, Krol M, et al. Increased content of tion in pediatric patients with asthma. Am Rev Respir Dis
hydrogen peroxide in the expired breath of cigarette smok- 1993; 148: 955–960.
ers. Eur Respir J 1996; 9: 652–657. 11. Zapletal A, Samanek M, Paul T. Lung function in chil-
6. Dekhuijzen PNR, Aben KKH, Dekker I, et al. Increased dren and adolescents. Methods, reference values. Basel,
exhalation of hydrogen peroxide in patients with stable Karger, 1987.
and un stable chronic obstructive pulmonary disease. Am 12. Hyslop PA, Sklar LA. A quantitative fluorimetric assay
J Respir Crit Care Med 1996; 154: 813–816. for the determination of oxidant production by poly-
7. Baldwin SR, Grum CM, Boxer LA, Simon RH, Ketai LH, morphonuclear leukocytes: its use in the simultaneous
Devall LJ. Oxidant activity in expired breath of patients fluorimetric assay of cellular activation processes. Anal
with adult respiratory distress syndrome. Lancet 1986; 1: Biochem 1984; 141: 280–286.
TECHNOLOGIES
FLEX
maxj�
150° F
65º e
CAPACIDAD
DE DESINFECCIÓN
251)) m2
150 M2
Slllm2
211'.!m:l!
3 m2
ONE FLEX SELF ReSPR 200 ReSPR 400 ReSPR 1000 ReSPR 2500 ReSPR 5000 Overwatch 2500 ECOBUS
Nota: Las áreas de capacidad de cada equipo contemplan una altura promedio de 3 mts
La Tecnología NCC, instalada en éste PURIFICADOR, fue probada

de manera satisfactoria contra el virus SARS nCOV-2 o
CORONAVIRUS que causa la enfermedad llamada COVID-19.
resprtech .con,
TECHNOLOGIES
FLEX
APLICACIÓN
Hogar BENEFICIOS
El FLEX reduce substancialmente los olores, humo visible
en el aire, y la población microbiana en ambiente
y supercies, utilizando la tecnología NCC. Especialmente
indicado para el control de la contaminación en espacios
Oficinas y consultorios interiores.
médicos
El FLEX es portátil, no requiere instalación y su funcio
namiento es sencillo. El mando a distancia le permitirá
controlar las funciones del equipo y regular las distintas
opciones de funcionamiento.
Áreas y habitaciones
hospitalarias
INSTALACIÓN
G
Instalar el FLEX es muy fácil: simplemente localice una
toma de corriente, conecte la unidad y coloque el equipo
dónde el flujo de aire pueda llegar a todas las zonas de la
Hoteles y restaurantes habitación.
Para usar el adaptador de corriente de 120/240 voltios

asegúrese de situar la unidad a una distancia de no más
O
de 2 metros de un enchufe. Se recomienda evitar el uso
Residencias de de una extensión de corriente por motivos de seguridad.
mayores
NASA2019
�i'��1
�
�
CLASS 1
MEDICAL
DEVICE
BASED
�
ON
svj@h,.'1--t4
-RESEARCH
�M•
TECI-INOLOGV
lnnovation of Excellence
resprtech .con,
ReSPR Technologies
ReSPR
FLEX
manual de usuario
www.resprtech.COM
Bienvenido
Bienvenido al ReSPR FLEX.
ReSPR FLEX fue diseñado para dar años sin problemas si se mantiene de la
forma correcta. Aún cuando el equipo sea cuidado, algunas piezas deben
remplazarse de forma periódica. Las piezas de recambio puedes adquirirlas con
un distribuidor autorizado o directamente con ReSPR Technologies.
(www.resprtech.com)
ReSPR
Technologies
2
ReSPR
Technologies
Contents
Inicio Rápido 4
Advertencias 5
Preparación y Uso 6
Diagramas 8
Rutina de Mantenimiento 12
Solución de Problemas 15
Límite de Garantía 17
Registros y Especificaciones 18
3
inicio rápido 1 2
1 Colocar el ReSPR FLEX sobre un mueble o repisa, nunca en el suelo.
Asegúrate de que haya espacio atrás y adelante del equipo para permitir
el flujo de aire.
2 Conecta el equipo con el cable incluido.
3 Coloca la batería en el mando a distancia.

3
4 Enciendelo con el control remoto o presionando el boton de la
pantalla. Ajusta el ventilador a un nivel de ruido cómodo. Mantén el
ReSPR FLEX en modo normal (NORMAL Mode). La pantalla debe decir
PCO (PhotoCatalytic Oxidation) o NCC (Natutal Catalytic Conversion).
Este es el modo estándar para usar en espacios habitados. El modo
ALTO (HIGH mode) para desinfecciones rápidas, no debe usarse Utiliza el modo AFUERA (AWAY MODE) para una
durante más de una hora si la habitación esta ocupada.
Ventilador Nivel de Tamaño de la habitación

5 desinfección máxima cuando el espacio no este
habitado. Al presionar el boton AWAY MODE
empezará un temporizador (de 2 a 8 horas).El
Purificación (Solo usar en modo ALTO)
ReSPR FLEX regresará al modo estandar cuando
el tiempo transcurra o cuando se presione el
4 boton de modo normal (NORMAL MODE).
NUNCA UTILIZAR AWAY MODE

CUANDO LA HABITACIÓN ESTE OCUPADA
4
Advertencias
Revisa esta lista antes de realizar cualquier limpieza o mantenimiento.
CUIDADO: Nunca usar el equipo cerca de una fuente de calor, fuego o combustibles / fluidos inflamables.
WARNING
CUIDADO: No encender hasta que todas las piezas (Célula incluida, Placa de Purificación, Ensamble posterior del filtro y Cubierta Trasera) estén
WARNING
instaladas correctamente.
PRECAUCIÓN: Mirar directamente la lámpara que hay dentro del equipo (más de 20 min.) puede dañar la vista.
CAUTION
PRECAUCIÓN: Nunca se debe ajustar los valores excediendo los metros cuadrados del espacio tratado.
CAUTION
PRECAUCIÓN: No utilizar AWAY MODE en espacios ocupados. Periodos cortos de tiempo expuestos a niveles de ozono mayores a 0.5 ppm puede
CAUTION
causar reacciones perjudiciales temporales.
PRECAUCIÓN: Se debe apagar y desconectar el equipo para su Limpieza/Desarmado/Re-ensamblado/Labores de mantenimiento.

CAUTION
5
Preparación y Uso
(Preparación Inicial)
Colocación Correcta Uso del ReSPR FLEX

• Asegúrate de colocar el equipo lo más cercano a la salida de aire 1. Conecta el cable al adaptador de corriente y el adaptador de corriente
de los conductos de climatización, y lo más lejano al retorno de la al equipo. (Asegúrate que la fuente de alimentación esté
instalación de HVAC (aire acondicionado). Esto nos asegura la correctamente conectada. El Cable de Corriente debe insertarse lo
circulación correcta de las partículas de oxidación producidas por el suficiente profundo en el adaptador de corriente, dejando que solo
ReSPR FLEX. quede un espacio de 1/8 de pulgada entre la parte más ancha del
cable y la pared del adaptador.
• Cada ReSPR FLEX es capaz de tratar un espacio de hasta aprox 275
metros cuadrados, siempre y cuando el aire circule por todo el espacio. 2. Inserte el enchufe en la toma de corriente.
Asegúrate que las puertas estén abiertas en los espacios que deseas
3. Encienda el equipo presionando el botón de encendido (POWER) y el
tratar.
botón de modo normal (NORMAL MODE). En la pantalla debe leerse
• Para asegurarnos el correcto funcionamiento, debe haber el mayor PCO (Photo Catalytic Oxidation) o NCC (Natural Catalytic Conversion).
espacio posible frente al ReSPR FLEX para que pueda procesar Esta es la forma òptima de operar el ReSPR FLEX de manera continua
eficientemente el aire en la habitación. en tu casa u oficina. Ajusta el ventilador a un nivel cómodo de ruido
usando los botones junto a la pantalla.
• Coloca el ReSPR FLEX en una repisa o sobre un mueble. Nunca lo
coloques en el suelo. 4. ReSPR FLEX viene con un control remoto y 1 batería para usarlo de
manera mas cómoda cuando coloques el equipo en una repisa.
6
Modos de Uso
Normal: Uso Continuo: 24/7; Alto (High): Limitar a 8 horas por
día; Afuera(Away): SOLO usar en espacios desocupados
Cuando utilizar modo NORMAL NORMAL Mode • Modo AFUERA (AWAY Mode) genera ozono para hacer una limpieza
• Modo Normal debe ser el modo continuo para usar el ReSPR FLEX en profunda en un espacio. Puede ser utilizado para eliminar humo, olor
espacios ocupados. de la cocina, hongos y esporas, virus y bacterias. Modo AFUERA (AWAY
mode) trabajará con un temporizador y al terminar su ciclo volverá al
Cuando utilizar modo ALTO HIGH Mode modo NORMAL (NORMAL Mode).
• El modo ALTO es el utilizado para purificación intensa, este elimina
• Para activarlo presiona el boton AWAY Mode. Cada vez que lo
contaminantes como el humo y olores significativos. No use modo
presiones incrementara el tiempo de 2:00, 4:00, 6:00 a 8:00 horas.
ALTO (HIGH MODE) por más de una hora en espacios con gente.
• Si al entrar a la habitación el modo AFUERA (Away Mode) esta activado,
• Cuando ReSPR FLEX esté en modo ALTO (HIGH Mode) la pantalla le
presiona el botón Normal/High para regresar al modo NORMAL.
pedirá que especifique los metros cuadrados. Presiona el botón
PURIFIER para arriba o abajo para ajustar el tamaño de la habitación.
NUNCA UTILICES EL MODO AFUERA (AWAY MODE) EN
Cuando utilizar modo DORMIR SLEEP Mode ESPACIOS OCUPADOS
• Desde el control remoto tendras acceso al modo dormir (SLEEP
Mode). Activandolo bajará la intensidad de la luz de la pantalla.
Cuando utilizar modo AFUERA AWAY Mode
7
Diagramas (Equipo)
Vista Frontal Vista Trasera Vista Lateral
1
1
2
2 2 3
3 1
3
1 Aguja de Ionización 1 Tornillo de Cubierta Trasera 1 Cubierta Trasera
2 Rejilla Frontal 2 Enganches de Cubierta Trasera 2 Vista Trasera
3 Panel de Control 3 Entrada Adaptador de Corriente 3 Vista Frontal
8
(Equipo)
Vista Trasera Vista Trasera Fuente de Alimentación

(Sin Cubierta Trasera) (Sin Filtro Trasero)
1
1
1 2
2
2
3 4
3 4
3
1 Tornillos de latón 1 Célula 1 Cable
2 Ensamble del filtro 2 Tuercas de Celda 2 Enchufe del cable
3 Enganches del ensamble 3 Conexión de Celda 3 Adaptador de Corriente
4 Placa de Purificación 4 Enchufe del Adaptador
9
Diagrams (Controls)
Mando a Panel de Control
distancia
1 6 2 3 4
2 5
3 4 1
5
1 Botón de Encendido 1 Botón de Encendido 5 Botón Normal/High
2 Control de Nivel de Purificación 2 Control de Nivel de Velocidad
3 Control de modo Normal/High 3 Control de Nivel de Purificación
4 Control del modo Away 4 Botón de modo AFUERA (AWAY)
5 Control del Nivel de Ventilación
6 Control del modo DORMIR (SLEEP)

10
(Controls)
Pantalla de Controles Pantalla Específica de Modos
Normal Mode
2 4
High Mode
5
1 3 6
Away Mode
1 Indica Velocidad del Ventilador 4 Advertencia del Nivel de Purificación 3 Pantalla Específica de Modos
Normal - Indicador de Tecnología (PCO o NCC)
2 Pantalla Específica de Modos 5 Recordatorio de Mantenimiento High - Indicador de los metros cuadrados
Away - Indica la duración (horas:minutos)
3 Indicador de Modo 6 Advertencia de modo AFUERA (AWAY)
11
Mantenimiento Rutinario Cómo desmontar la cubierta trasera
1. Apagar el equipo con el Botón de Encendido/Apagado.
2. Desconectar el equipo de la corriente y desconectar el cable de la parte

Para que el equipo ReSPR FLEX funcione correctamente, se debe limpiar
trasera.
cada 60 a 90 días. Cada mes la pantalla te recordará la limpieza del equipo.
La mejor forma de ver si el filtro necesita limpieza es revisar si la rejilla 3. Desatornillar y quitar el tornillo de la cubierta trasera, localizado arriba
frontal tiene polvo. Si la rejilla se encuentra sucia, deberías limpiar el filtro del puerto de conexión.
de lo contrario solo presiona el botón para resetear el recordatorio y te
4. Con dos manos, aprieta los costados de la cubierta donde están los
avisará 30 días después.
enganches, a la mitad de la cubierta y levanta suavemente la cubierta
Para quitar y limpiar el filtro necesitarás un destornillador Philips #2 hasta que se suelte.
5. Inclina la cubierta hacia arriba, hasta que se libere.
6. Limpia la cubierta con un trapo y

déjala a un lado.
Como retirar y limpiar el filtro
1. El equipo debe estar apagado y desconectado de la toma de
corriente para Limpiar/Desarmar/Reensamblar/Dar Servicio.
2. Retira los dos tornillos de latón localizados en la parte superior. La

primera vez que lo hagas, necesitaras un destornillador.
3. Retírala con cuidado
4. Enjuaga el filtro con agua templada, elimina el exceso de agua y

déjalo secar por una hora antes de volver a colocarlo en el equipo.
12
Recolocar el Filtro 5. Si la aguja de ionización esta sucia, limpia con cuidado utilizando
1. El lado plano más grande se coloca hacia adentro del equipo. Deberá algodón con una solución de alcohol o frotándolo con alcohol.
tener una etiqueta de Advertencia que dice lo siguiente: “Caution:
Reinstall Filter After Cleaning” (Reinstalar Filtro desp ués de Limpiarlo) Recolocando la rejilla frontal
1. Alinea la rejilla frontal con el equipo. Ten cuidado de no dañar la
2. Inserta la parte inferior del filtro en las pestañas y presiona para asentar.
aguja de ionización que está en el centro del equipo.
3. Atornilla los dos tornillos de latón en los huecos localizados en las
2. Inserta los tornillos uno a la vez, atornillándolos hasta la mitad de su
esquinas superiores del marco del filtro. Apriétalos con la mano. No es
recorrido. Una vez que los cuatro tornillos estén en su lugar,
necesario usar un destornillador.
apriétalos hasta el final.
Reensamblado de la Cubierta Trasera

1. Coloca la pestaña de la parte superior de la cubierta por arriba del
marco del filtro. Presiona la cubierta contra la parte trasera del equipo
hasta que las pestañas laterales se enganchen.
2. Coloca el tornillo de la cubierta trasera en el hueco y atornillalo.
Como quitar y limpiar la rejilla frontal

1. Localiza los cuatro tornillos de la rejilla frontal en las cuatro esquinas
del mismo.
2. Usando un destornillador, con cuidado, retira los cuatro tornillos.

Coloca la rejilla donde sea fácil localizarla para recolocarla.
3. Retira la rejilla frontal con cuidado y asegúrate que la aguja de

ionización (localizada en la parte superior central) no esté dañada.
4. Limpia la rejilla frontal usando aire comprimido, aspiradora y un

trapo húmedo y déjalo a un costado.
13
Recordatorios en Pantalla
Cuando tu ReSPR FLEX necesite mantenimiento, un mensaje aparecera en la
pantalla.
• Limpiar el Equipo (Perform Cleaning) – Este mensaje aparecerá cada 30

días. Verifica que la rejilla frontal no tenga suciedad. Si estuviera sucia,
debes limpiar e filtro como lo detallamos en la rutina de mantenimiento
de la pagina 12. Si la rejilla no tiene polvo, solamente presiona el botón
de resetear el recordatorio (Reminder) y el ReSPR FLEX te lo recordará
de nuevo 30 días mas tarde.
• Cambiar la Placa (Replace Plate) – Este mensaje aparece cuando la

lámina de purificación ya llego al final de su vida útil y es necesario
cambiarla. Para solicitar algún recambio, puedes hacerlo a través de un
distribuidor o directamente con ReSPR Technologies (www.resprtech.
com). Sigue las instrucciones que incluye tu refacción para cambiar la
placa de purificación.
Un mensaje aparecerá
• Cambiar la Célula (Replace Cell) - Este mensaje aparece cuando la célula en pantalla cuando tu
ya llego al final de su vida útil y es necesario cambiarla. Para solicitar ReSPR FLEX necesite
algún recambio, puedes hacerlo a través de un distribuidor o mantenimiento.
directamente con ReSPR Technologies (www.resprtech.com). Sigue las
instrucciones que incluye tu refacción para cambiar la celda.
14
Solución de Problemas
Si el Equipo no Enciende Si el equipo esta operando en modo ALTO (High Mode) o modo
1. Verifica que el enchufe este conectado a un contacto con corriente. AFUERA (Away Mode) pero no se percibe que se este purificando.
2. Asegúrate que el cable este completamente insertado en el equipo. Asegúrate que la placa de purificación esté limpia (Ver Paso 4).
(dejando menos de 1/8 de pulgada de espacio) al adaptador. 6. Posiblemente la placa de purificación no funcione correctamente y
3. Asegúrate de que el enchufe del adaptador este completamente requiere de un cambio. Intenta colocando otra placa.
insertado en el hueco de la vista trasera del equipo. 7. Revisa los brazos de contacto que tocan la placa para asegurar que
4. Asegúrate de haber presionado el botón de Encendido. estén haciendo contacto correctamente con la malla metálica de la
placa.
5. Si el botón de Encendido del equipo no funciona, prueba con el
control remoto. Si ninguno de los dos botones funcionan, contacta un 8. Asegúrate que los brazos de contacto que tocan la placa estén limpios.
distribuidor o a ReSPR Technologies Límpialos con un paño y alcohol.
(www.resprtech.com). 9. Apaga las luces de la habitación y observa a través de la rejilla frontal.
Si funciona correctamente debe producir una luz azulada.
15
Retirar y limpiar la Placa de Purificación La Placa de Purificación genera un arco eléctrico, un ruido del arco
1. Sigue las instrucciones para retirar la cubierta trasera y el Filtro en la o un olor a quemado:
página 12. Esto significa que la Placa de Purificación está dañada y debe remplazarse.
Aunque el equipo marque o no que se requiere remplazar la Placa. Para
2. Sujeta la Placa de Purificación por la parte de cerámica y tira
pedir un remplazo contacta a un distribuidor o a ReSPR Technologies (www.
suavemente hasta que salga de los canales laterales.
resprtech.com).
3. Usando una mezcla 50/50 de agua templada y amoniaco, o en su lugar
100% de Vinagre, remoja durante 8 a 10 horas. No exceder las 10 horas. La luz de la Célula no Enciende
Usando un cepillo de cerdas suaves frota y limpia la malla. Enjuaga.
1. Asegúrate que la conección de la Célula esté colocada correctamente
Asegúrate de que la malla seque por completo antes de reinstalarla.
a la salida de corriente.
4. Utiliza un paño suave y frota con alcohol para limpiar los contactos a. Sigue las instrucciones para retirar la cubierta trasera y el Filtro
que tocan la Plca de Purificación. de la Página 12.
5. Sujetando la Placa de Purificación desde los extremos de cerámica b. Revisa si el conector de la célula está correctamente ensamblado.
alineate a los canales en ambos costados y suavemente inserta la placa Para eso presiona el conector de manera que las pestañas
de purificación. alcancen su posición y se enganchen.
2. Si la Célula sigue sin funcionar, necesitará un cambio. Contacta un

distribuidor o a ReSPR Technologies (www.resprtech.com).
16
Garantía Limitada
Tu ReSPR FLEX esta garantizada de estar libre de defectos en materiales y fecha de la compra inicial y le cubrirá el tiempo restante de la misma. Para
fabricación, en condiciones normales de uso, por 1 año a partir de la otro servicio de información, por favor visite: www.resprtech.com
fecha de compra. La garantía solo es aplicable para el comprador original
y está sujeta a los siguientes términos: Esta garantía no cubre partes del
ReSPR FLEX que requieran remplazo en las condiciones normales. Esto Limitaciones adicionales y Exclusiones
incluye la Placa de Purificación y el Filtro. También la Célula requiere
Cualquier garantía que pueda estar implícita en relación con su compra
remplazo periódico, la Célula está garantizada por 1 año al igual que el
o uso de ReSPR FLEX, incluida cualquier garantía de comercialización o
Equipo. Cualquier daño o mal funcionamiento ocasionado por
negligencia, abuso o uso distinto al estipulado en el Manual de Usuario cualquier garantía de aptitud para un propósito particular, se limita a la
o no estará cubierto por está garantía. De la misma manera, cualquier duración de esta garantía. Algunos estados no permiten limitaciones sobre
defecto o daño causado por un servicio no autorizado o el uso de piezas la duración de una garantía implícita, por lo que es posible que las
que no sean originales de ReSPR, no estará cubierto. ReSPR Technologies limitaciones anteriores no se apliquen en su caso.
podrá reparar o remplazar las piezas defectuosas del ReSPR FLEX que
Su desagravio por incumplimiento de esta garantía se limita al desagravio
estén cubiertas por esta garantía. Como política de garantía ReSPR
expresamente provisto anteriormente. En ningún caso ReSPR Technologies
Technologies no devolverá al cliente el valor de la compra.
será responsable de ningún daño consecuente o incidental en el que pueda
Para obtener una Garantía de Servicio usted debe devolver el equipo incurrir en relación con su compra o uso de ReSPR FLEX. Algunos estados no
defectuoso ReSPR FLEX o las piezas que no funcionen con el recibo de la permiten limitaciones sobre la duración de una garantía implícita, por lo que
compra a su distribuidor. Todos los gastos de transporte de piezas y es posible que las limitaciones anteriores no se apliquen en su caso.
equipos dentro de esta garantía correrán por cuenta del comprador. A
menos que esta garantía se extienda o renueve directamente por ReSPR Esta Garantía le otorga derechos legales específicos, y es posible que
Technologies, cualquier reparación o remplazo tendrá la garantía con también tenga otros derechos que varían de un estado a otro.
17 17
Registros Especificaciones
Fecha de Compra:
Equipo
Medidas: 30 alto x 23 ancho x 30 largo cms
Peso: 4,7 kgs.
Numbero de Modelo: ReSPR FLEX Alcance: Hasta 279 m2
Fuente Alimentación
Fuyuang Switching Power Supply
Número de Serie:
Model: FY3803000
Input: 100-240VAC 50/60Hz 2.5A Output: 38VDC 3A
Vea la etiqueta de la alimentación de corriente para certificados
Nombre del Distribuidor: y advertencias.
Célula
Salida de modo NORMAL
Teléfono del Distribuidor:
Purification Plate
Salida en modo ALTO (High Mode): 25-360mg de ozono por hora
Aguja de Ionización
24 a 30 KV, 20-30 Khz Ion Generation Pulsator
Información al Consumidor Nivel Sonoro

Velocidad / dB: 1: 23 dB, 2: 29dB, 3: 34 dB, 4: 47 dB, 5: 51dB.
ReSPR Technologies declina toda responsabilidad por todos los daños como
resultado de un uso inadecuado de la unidad o en caso de manipular la
unidad.
18
ReSPR Technologies
www.resprtech.com
19
ReSPR OVeRWATCH Technologies
Dropped ceiling installed natural air system

Discreet or concealed installation
12/24/120/220 volt optional installation
NCC cell monitoring indicator included
Low maintenance – Low cleaning required
THE TECHNOLOGY SPECIFICATIONS

The ReSPR OVeRWATCH substan- OVeRWATCH EU60100
tially reduces odors, visible
12/24 VDC,
smoke in the air, and microbial electrical 120/220 VAC, 15 watts*
populations in air and on surfac- 50/60 HZ
es, utilizing the NCC technology. Tangencial fan. safety switch
mechanical
100 cfm installed
Perfect for indoor pollution con- 60cm L x 60cm W
dimensions 24”H x 24”W x 5”D
trol, odor reduction, contamina- x 12cm D
tion prevention, etc...
weight 13 pounds 6 kilograms
NCC consists of a special UV light

max temp 150 F 65oC
and photocatalyst target, creat-
ing an Advanced Oxidation * Based on nominal line voltage
Process containing several
friendly oxidizers.
BENEFITS
Up to 99.999% kill rate on surfaces
Effective against bacteria, virus and mold
Easy installation. PLug and play operation
Effective against odors and VOC’s
Safe, discreet and silent
*Scientiﬁc tests have demonstrated the use of ReSPR surface and air puriﬁers substantially
reduce microbial populations on surfaces. These products are not intended to diagnose,
treat, or cure any disease.
ReSPR Technologies
ReSPR OVeRWATCH
Technologies
APLICATIONS
Any dropped ceiling with 60x60 cm (2x2 ft) tiles
The ReSPR OVeRWATCH s
ideally applicable to Hospital areas and operating rooms
situations in which ducts Nursing homes
are not easily accessible
and where low mainte- Business offices
nance, low cleaning, or
discreet installation might Hotels’ lobbies and restaurants
also be an advantage. Residential homes
Indoors plant growers
INSTALATION DETAILS
ReSPR OVeRWATCH can be installed in any
dropped ceiling directly by replacing an existing
tile, close to the source of pollution and/or the
place of higher occupancy.
ELECTRICAL REQUIREMENTS
• To use the 120/240 volt plug, be sure to locate

the unit within 2m of a standard 120/240 volt
grounded outlet. Long term use of an extension
cord is not recommended due to safety consider-
ations.
• Installation must be by a licensed professional.

OVeRWATCH works without any filter and only
needs a small intervention every 2 years (replace-
ment of the NC2I cell).
And installing OVeRWATCH is amazingly simple: just

remove an exisiting tile, connect the unit to the
main and place the OVeRWATCH in lieu and place
of the removed tile, on top of the metal grid. Job
done.
DISTRIBUTED BY
www.resprtech.com contact your ReSPR distributor or send an email to info@resprtech.com

TECHNOLOGIES
DESINFECCIÓN
CONTINUA
SIN PERSONAL
EL MUNDO NO VOLVERA A DETENERSE
CONTENIDO
NUEVA NORMALIDAD
RESUMEN
SOLUCIÓN
INNOVACIÓN TECNOLÓGICA
EQUIPOS
BENEFICIOS
CLIENTES
CONTACTO
resprtech.com
TECHNOLOGIES
NUEVA NORMALIDAD
El Regreso a la "Nueva Normalidad” traerá consigo nuevos retos
para los cuales, todo el mundo deberá estar preparado.
Los "nuevos" clientes buscarán ante todo un espacio que no ponga

en riesgo su salud por contagio de virus y
bacterias.
ReSPR es la solución para ofrecer a tus "nuevos"

visitantes y personal de trabajo la confianza sanitaria
requerida en la actualidad.
ReSPR es el único dispositivo en el mercado que utiliza tecnología

NCC, la cual está sustentada en estudios
realizados por la NASA.
ReSPR desinfecta de forma continua 24 horas al día, los 7 días de

la semana sin necesidad de personal que opere esta tecnología,
ni administración de insumos químicos que pueden ser tóxicos y
retrasen los tiempos operativos y aumenten los costos.
El diseño de ReSPR permite que sea ubicado en

cualquier conducto o espacio cerrado, garantizando la
desinfección del aire y superficies hasta el último rincón,
con una efectividad del 99.9%
ReSPR es la solución para satisfacer los estándares
sanitarios que demandará la nueva normalidad.
La Tecnología del futuro... hoy.
resprtech.com
TECHNOLOGIES
RESUMEN
Bacterias, hongos,
esporas, ácaros y
cualquier
microorganismo
que pueda causar
daño al ser
humano.
Sin duda nuestra

tecnología es la
mejor opción para
desinfectar un
espacio cerrado, ya
que solo requiere
La tecnología para erradicar de conectarlo a
manera efectiva 99.9 % de virus y corriente y te
bacterias en el aire y superficies es olvidas de virus y
sin duda, una desinfección cuántica, bacterias por los
manos libres y que trabaja 24 horas siguientes 18
al día los 365 días del año. meses.
ReSPR a través de su tecnología

NCC es capaz de eliminar virus.
resprtech.com
TECHNOLOGIES
SOLUCIÓN
La pandemia del 2020 y la

nueva normalidad nos han
puesto una tarea muy complica-
da a la hora de implementar los
equipos y sistemas de
desinfección que harán que
cuidemos a los nuestros.
ReSPR ofrece, sin duda, la
tecnología mas efectiva,
práctica y económica del
mercado. Tan solo conectando
los equipos de ReSPR en un
espacio cerrado, puedes
disfrutar de la tranquilidad de
estar protegido.
Además de ser la solución más
efectiva, práctica y económica.
También es la más segura, ya
que como actúa a niveles cuán-
ticos es totalmente inocua al ser
humano, solo ataca
microorganismos. Esto lo
respaldamos con numerosos
estudios científicos y
certificados médicos como el
CLASS 1 MEDICAL DEVICE de
la Comunidad Económica
Europea
resprtech.com
TECHNOLOGIES
INNOVACIÓN TECNOLÓGICA
Basada en estudios de la
NASA. Nuestra tecnología
NCC ha sido mejorada y
patentada, a través de mas
de 20 años de experiencia.
Aplicamos
tecnología del
espacio para dar soluciones
en la tierra.
Esto nos ha llevado a
recibir en el 2019 el
premio a la
EXCELENCIA EN
INNOVACIÓN
TECNOLÓGICA
otorgado por la
NASA
NASA 2019
Innovation of Excellence
resprtech.com
TECHNOLOGIES
TECNOLOGÍA NCC
La tecnología NCC
(Natural Catalytic Converter)
utiliza una lámpara de rayos
UV y una rejilla metálica con
recubrimiento hidrófilo, para
generar una reacción iónica
que genera grupos hidroxilos
El convertidor
catalítico
transforma la
humedad del
ambiente
(H2O)
en agua oxigenada
(H2O2).
resprtech.com
TECHNOLOGIES
FLEX
KG
70 watts 16 libras
120/220 VAC, 7 kilos
50/60 HZ
12 X 12 X 9 PULG 150º F
31 X 31 X 23 65º C
CMS
500 m2
capacidad
de desinfección
250 m2 250 m2
150 M2
100 m2
50 m2 40 m2 50 m2
20 m2
3 m2
Nota: Las areas de capacidad de cada equipo contemplan una altura promedio de 3 mts
El FLEX es nuestro equipo más vendido por su versatilidad y

efectividad. Con ajustes en el equipo y por control remoto, en este
equipo puedes regular la potencia de purificación y ventilación.
resprtech.com
TECHNOLOGIES
one
KG
20 watts 3 libras
120/220 VAC, 1.5 kilos
50/60 HZ
6.7 X 6 X 7 PULG 150º F

17 X 17 X 18 65º C
CMS
500 m2
capacidad
de desinfección
250 m2 250 m2
50 M2
150 m2
100 m2
40 m2 50 m2
20 m2
3 m2
Compacto y Portátil este equipo es el ideal para habitaciones de hotel, con-

sultorios médicos, despachos, estancias en el hogar, etc. Cuenta con contro-
les en el equipo y a control remoto para regular la desinfección.
resprtech.com
TECHNOLOGIES
self
KG
1.5 onzas
24 a 30 43 gramos
horas
3.4 X 2.9 X 1 PULG 150º F

8.7 X 7.5 X 2.5 65º C
CMS
500 m2
capacidad
de desinfección
Personal 250 m2 250 m2
150 m2
100 m2
50 m2 40 m2 50 m2
20 m2
1 m2
El SeLF es un equipo personal. Con este equipo agregas una capa de

protección para llevar contigo. Se recarga por medio de un cable USB y
la batería dura de 24 a 32 horas desinfectando.
resprtech.com
TECHNOLOGIES
HVAC
KG
12 a 80 watts 1 a 7 libras
120/220 VAC, 0.5 a 3.5 kilos
50/60 HZ
9.6 X 9.6 X 11 PULG 150º F

24.5 X 24.5 X 65º C
28.5 CMS
500 m2
capacidad
de desinfección
Desde 20 hasta 500 m2 250 m2 250 m2
150 m2
100 m2
50 m2
40 m2
20 m2
3 m2
Los equipos HVAC como su nombre lo indica es un equipo para instalar

en conductos de climatización y ventilación. Este equipo está disponible
en 5 capacidades de desinfección, desde 20 m2 hasta 500 m2.
resprtech.com
TECHNOLOGIES
ecobus
KG
15 watts 3 libras
12/24 VDC, 1.5 kilos
50/60 HZ
10.2 X 7.8 X 3 PULG 150º F

26 X 20 X 65º C
7.6 CMS
500 m2
capacidad
de desinfección
50 M2 250 m2 250 m2
150 m2
100 m2
50 m2 50 m2
40 m2
20 m2
3 m2
Diseñado especialmente para el transporte, el Ecobus es el equipo

ideal para minivans, autobuses, barcos, trenes, etc.
resprtech.com
TECHNOLOGIES
overwatch
KG
20 watts 13 libras
120/220 VAC, 7 kilos
50/60 HZ
24 X 24 X 5 PULG 150º F
60 X 60 X 65º C
12 CMS
500 m2500 m2
capacidad
de desinfección
250 M2 250 m2 250 m2
150 m2
100 m2
50 m2 40 m2 50 m2
20 m2
3 m2
OverWatch es un equipo diseñado para falso techo, con una medida

estándar de 60 x 60 cms y tan solo 12 cms de altura, se coloca
fácilmente en el techo y tiene un aspecto muy limpio y profesional.
resprtech.com
TECHNOLOGIES
ductstation
KG
59, 79 y 99 watts 36, 40 y 45 libras

120/220 VAC, 16, 18, y20 kilos
50/60 HZ
37 X 10 X 17.5 PULG 150º F

93 X 24 X 44 65º C
CMS
1000 m2
capacidad
de desinfección 750 m2
500, 750 y 1000 M2 500 m2
250 m2
250 m2 250 m2
100 m2
50 m2 40 m2
25 m2
3 m2
AP 50 AP 3001 Self Ductstation Ductstation Ductstation Ductstation Ductstation Ductstation Ductstation Overwatch 2500
Mini Mini 2 Box Box 2 10 15 20
DuctStation es el equipo industrial, con una caja de acero inoxidable, es

el equipo mas resistente y fácil de limpiar. Diseñado para cámaras de
almacenaje, preparación de alimentos, cámaras de refrigeración, etc.
resprtech.com
TECHNOLOGIES
BENEFICIOS
DESINFECCIÓN CONTINUA DEL AIRE
DESINFECCIÓN CONTINUA DE SUPERFICIES
AHORRO EN PRODUCTOS DE LIMPIEZA Y DESINFECCIÓN
AHORRO EN PERSONAL
AHORRO POR ABSENTISMO LABORAL
AHORROS DIRECTOS E INDIRECTOS EN MEDICAMENTOS

Y SEGUROS LABORALES
FORTALECER LA IMAGEN INSTITUCIONAL AL CUIDAR

LA SALUD DE LOS CLIENTES Y EMPLEADOS
EVITA LA FORMACIÓN DE HONGOS
ELIMINA LOS MALOS OLORES
resprtech.com
TECHNOLOGIES
$)*&+!&, ,#!*,-&$.',
NUESTROS CLIENTES &+ /01*$' &
resprtech.com
TECHNOLOGIES
resprtech.com
TECHNOLOGIES
ACERCA DE NOSOTROS
ReSPR Technologies se funda en Dallas, Texas
Se establece en Europa en 2002
Head Quarters estan en Dallas (EU) y

Malaga (España)
Fabricas en Dallas, Tennessee, Polonia y China
Presencia en
más 27 países
Síguenos en redes sociales
Derechos Reservados ReSPR

info@resprtech.com
+34 952 004 975
resprtech.com
DECLARATION OF CONFORMITY
The Manufacturer ReSPR Technologies EUROPE declares under its own responsibility that the device
Model and Article No. Denomination CND Classification No Technical File
System for treatment and sanitization of air ducts, surfaces,

ReSPR medical apparatus in general, sanitization of disposable devices
OVeRWATCH
for general purpose and specialty, clothing, medical disposable
and reusable.
V07 NW990-0007
CLASSIFICATION I
Satisfies all applicable dispositions and the essential requirements (Annexe 1) of Directive 93/42CEE on
Medical Devices, modified by the Directive 2007/47/CE.
The Medical Device is manufactured also in conformity with the following Technical standards:
CEI EN 60601-1 (CEI 62.5) for the applicable points
Moreover ReSPR Technologies EUROPE is committed to:
- Keep the technical documentation specified at point 3 of Annex VII of Directive 93/42/CEE at the
disposal of the Notified Body for a period of five years from the date of manufacture of the product. The
aforesaid documentation supports this declaration of conformity;
- Maintain an appropriate system for the monitoring of the device, in the phase successive to that of
production, and to apply eventual necessary corrective measures, as prescribed in Annex VII.
It is therefore declared that the above-named device will be put on the market with the
Cl ass 1 CE mark, according to the dispositions of Article 17 of Directive 93/42/CEE,
modified by the Directive 2007/47/CE.
Date 26 September 2020

Signature of Legal Representative
Certified by:
ReSPR Technologies Europe – Pasaje Río Ulla, nave 5 – Málaga 29196 - Spain | www.resprtech.com
Limited Lamp Data Sheet
CSPR/2G11
www.casprgroup.com
Dimensions
A - Base face to end of lamp (max) 212 mm
B - Radiating length (max) 187 mm
Base 2G11
Electrical Data ( nominal values )
Lamp Wattage 32 W
Lamp Current 800 mA
Lamp Voltage at High Frequecy 42 V
Physical Data
Radiation wavelength 254 nm
UV Output 253.7nm (100hr) 9W
2
Intensity @ 1m 90 µW/cm
Rated Average Life * 25000 hrs
*Average rated life when operated on an electronic high-frequency ballast
Maintenance curve
The useful life is determined

on the operation condition of the lamp
(for example type of ballast, ignitor used,
cooling conditions, on/off cycle, etc.)
Note: Performance data are valid under laboratory conditions.

The rights are reserved to change the data.
LTCQ32W HOL_ 2G11_r0.xlsx LightTech, Inc. Confidential 2017.05.19

Re SPR

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Re SPR

Uploaded by

Copyright:

Available Formats

LABORATORY

REPORTING COMPLETED BY:

Protocol and Procedures

Methicillin Resistant Staphylococcus aureus (MRSA)

Enteroccus faecalis (VRE) Pseudomonas aeruginosa

Feline Calicivirus Trichophyton interdigitale

Influenza A (H1N1) MS2 Bacteriophage (MS2)

Results of the Study MS2 Bacteriophage ATCC 15597-B1

Percent Log10 Reduction

Time Zero Control 3.50E+04 N/A

Control 1.40E+04 N/A

MS2 Bacteriophage 15597-B1

Copyright © Microchem Laboratory,Proprietary

Average Log Average Percent

CASPR Device 6 hours 2 ≤0.80 ≤1.05 ≥3.42 ≥99.96%

Results for Feline calicivirus, ATCC VR-782:

Results of the Study (cont.)

Average Log Average Percent

CASPR Device 6 hours 2 1.30 ≤1.05 ≥3.17 ≥99.93%

Results of the Study E. faecalis ATCC 51299 (VRE)

Per cent Log 1 0

Control 2.60E+05 N/A

E. faecalis 51299 (VRE)

Results of the Study S. aureus ATCC 33592 (MRSA)

Average Percent Average Log10

Results of the Study P. aeruginosa ATCC 15442

Average Percent Average Log10

Results of the Study T. interdigitale ATCC 9533

Percent Log10 Reduction

Time Zero Control 8.00E+02 N/A

Control 2.00E+02 N/A

Staphylococcus aureus (MRSA) ATCC 33592

Enterococcus faecalis (VRE) ATCC 51299

Trichophyton interdigitale ATCC 9533

Aspergillus brasiliensis ATCC 9642

MS2 Bacteriophage (MS2), ATCC 15597-B1

Feline calicivirus (FCV), ATCC VR-782

LAB TEST REPORT PROPRIETARY & CONFIDENTIAL 1

Taxonomically, SARS-CoV-2 is a strain of severe acute respiratory syndrome-

LAB TEST REPORT PROPRIETARY & CONFIDENTIAL 2

Test Microorganism Information

LAB TEST REPORT PROPRIETARY & CONFIDENTIAL 3

Materials and Methods

LAB TEST REPORT PROPRIETARY & CONFIDENTIAL 4

NCC® Technology utilizes a revolutionary and doped hydrophilic photo catalytic

The accumulated reduction of SARS-CoV-2 titer, calculated in relation to the

LAB TEST REPORT PROPRIETARY & CONFIDENTIAL 5

LAB TEST REPORT PROPRIETARY & CONFIDENTIAL 6

ReSPR Group Inc

Full laboratory reports available on request.

LAB TEST REPORT PROPRIETARY & CONFIDENTIAL 7

Designing effective methods of SARS-CoV-2 inactivation that can be applied in daily

MATERIALS AND METHODS

Materials infection and sample collection

Table 1. Evaluated treatments

Virus dose Exposure time (min) Treatment

1x105 15, 30, 60, 120, 360,

Model and Article No. Denomination CND Classification No Technical File

System for treatment and sanitization of air ducts, surfaces,

Moreover ReSPR Technologies EUROPE is committed to:

Date 26 September 2020

Human & Environmental Risk Assessment

Edition 1.0 April 2005

Q. Jöbsis, H.C. Raatgeep, S.L. Schellekens*, W.C.J. Hop**,